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ABSTRACT 
Psychomotor stimulants are the most commonly 
prescribed medications for the treatment of ADHD in 
children and adults. A vast literature has evolved 
concerning the efficacy and potential side effects of 
these drugs. Although stimulants are generally regarded 
as safe and effective, there is concern that potential 
problems may have been overlooked. Specifically, there 
is some literature indicating that, at least in some 
cases, stimulant medications may produce significant 
disruptions in social behavior. To investigate these 
effects, a number of different measurements were 
employed with preschool children, including direct 
observations during times of play, a social reinforcer 
assessment and a number rating scale/interview measures. 
The results indicate that three of the six participants 
displayed heightened levels of anxiety or stereotyped 
behaviors in specific settings while taking their 
prescribed dose of stimulant medication. The social 
reinforcer assessment revealed that the value of social 
reinforcers (i.e., playing with others) decreased for 
two of the participants while on their prescribed dose 
of medication. A corresponding increase in the value of 
nonsocial reinforcers (i.e., playing alone or quiet 
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time) was observed for both of these participants as 
well. Another participant displayed the opposite effects 
in the reinforcer assessment while taking stimulant 
medication. The value of social reinforcers appeared to 
increase for this participant while taking the 
prescribed dose of stimulant medication. The findings 
from the rating scales were inconclusive, and did not 
correspond well with the direct observations. The 
relevance of these findings from the direct and indirect 
measures as well as the reinforcer assessment will be 
discussed. 
 
Key Words: Attention deficit hyperactivity disorder, 
behavioral pharmacology, play, social behavior, stimulant 
medication 
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CHAPTER 1: INTRODUCTION 
Attention deficit hyperactivity disorder (ADHD) is the 
most commonly diagnosed childhood behavior disorder. 
Current consensus is that the disorder affects 
approximately 3 to 10% of school aged children (Murray & 
Patel, 2001). It has been estimated that three to six 
million children are currently receiving stimulant 
medication, with an upward trend in recent decades that is 
expected to continue (Murray & Patel, 2001; Safer, Zito & 
Fine, 1997). Approximately 90% of children receiving a 
diagnosis of ADHD are treated with stimulant medication at 
some point in their lives (Pelham, 1993). In addition, 
there is an increasing trend to prescribe stimulant 
medication to young children (i.e., ages 3 to 5) (Zito, 
Safer, dosReis, Gardner, Boles & Lynch, 2000). There is a 
vast literature concerning the efficacy and side effects of 
stimulant medications. The tenor of this literature is that 
stimulants are both effective and benign. 
Overview of the Literature 
Stimulants have been the most exhaustively researched 
medication in all of child psychiatry. Over the last 
several decades, the short-term efficacy of stimulants for 
the treatment of the core symptoms of ADHD (i.e., 
inattention, hyperactivity) has been well documented. The 
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literature indicates that 70% to 96% of children between 
the ages of 6 and 18 have a positive response for the 
treatment of the core symptoms of ADHD (Barkley, 1977a; 
Elia, Borcherding, Rapoport & Keysor, 1991). Controlled 
studies evaluating the effects of stimulants have 
demonstrated their effectiveness for decreasing the 
occurrence of interrupting class, reducing task-irrelevant 
activity in school, improving attention and compliance, 
increasing attentiveness during games of baseball, 
improving parent-child interactions, improving teacher-
child interactions and decreasing the occurrence of overt 
and covert aggression (Barkley et al., 1985; Barkley, 1989; 
Jacobvitz, Sroufe, Stewart & Leffert, 1990; Pelham, Gnagy, 
Chronis, Burrows-MacLean, Fabiano, Onyango, Meichenbaum, 
Williams, Aronoff, Steiner, 1999; Schachter, Pham, King, 
Langford, Moher, 2001; Spencer, Biederman, Wilens, Harding, 
O'Donnell, Griffin, 1996; Swanson, McBurnett, Wigal, 
Pfiffner, Lerner, Williams, Christian, Tamm, Willcutt, 
Crowley, Clevenger, Khouzam, Woo, Crinella & Fisher, 1993; 
Tallmadge and Barkley, 1983; Whalen et al., 1980; Whalen et 
al., 1981).  
Although the literature pertaining to the effects of 
stimulant medications on the core symptoms of ADHD is quite 
convincing, the efficacy of these drugs for the treatment 
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of ancillary features of ADHD is not as clear. Stimulants 
have not been shown to be effective for improving social 
skills nor have they shown any consistent benefit in 
academic performance (Carlson & Bunner, 1993; Gittleman-
Klein & Klein, 1976; Rie, Rie, Stewart & Ambuel, 1976a; 
Rie, Rie, Stewart & Ambuel, 1976b).  
Difficulties with peer relationships are extremely 
common in children diagnosed with ADHD. These children tend 
to engage in controlling behavior (i.e., being bossy), 
are more aggressive than same-age peers, and have fewer 
reciprocal social exchanges with peers (Landau & Milich, 
1988). Reports of stimulant-induced decreases in aggression 
are common, yet few studies have demonstrated improvements 
in prosocial behavior. As will be discussed in more detail 
later, several studies have shown that stimulants have the 
potential to produce significant disruptions in social 
behavior (Schliefer, Weiss, Cohen, Elman, Cvejic & Kruger, 
1975; Whalen, Henker, Collins, McAuliffe & Vaux, 1979).   
Additionally, children diagnosed with ADHD frequently 
exhibit academic problems, including poor performance in 
math and reading. Although some studies have suggested that 
stimulant-induced improvements in attention span may 
improve scholastic achievement, there has been little 
evidence to indicate that stimulants produce any 
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significant improvements in direct measures of academic 
skills, such as information retention, acquisition of new 
skills or IQ scores (Gittleman-Klein & Klein, 1976; Rie et 
al., 1976a; Rie et al., 1976b; Swanson et al., 1993). 
Although stimulants have been extensively studied in 
children aged 6 to 18, relatively few studies have 
specifically investigated their effects in children under 
six years of age. Since 1975, only nine double-blind 
placebo controlled medication evaluations using stimulants 
have been conducted with children in this age range 
(Connor, 2002). Of these nine studies, eight reported 
significant improvements for the core symptoms of ADHD 
while taking stimulant medication (Barkley, 1988; Barkley, 
Karlsson, Strzelecki, Murphy, 1984; Byrne, Bawden, DeWolfe, 
Beattie, 1998; Conners, 1975; Cunningham, Siegel & 
Crawford, 1985; Handen, Feldman, Lurier & Murray, 1999; 
Mayes, Crites, Bixler, Humphrey & Mattison, 1994; Monteiro-
Musten, Firestone, Pisterman, Bennett & Mercer, 1997). 
Several of these studies documented specific improvements 
in behavioral domains, including hyperactivity and 
impulsivity (Conners, 1975; Mayes et al., 1994; Byrne et 
al., 1998) as well as improvements in interpersonal 
domains, including decreases in inappropriate social 
interaction and aggression (Barkley, et al., 1984; Barkley, 
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et al., 1988, Byrne, et al., 1998; Monteiro-Musten, et al., 
1997). Schliefer and colleagues (1999) determined that the 
effects of stimulants are more variable in preschool 
children and did not show clear beneficial effects for most 
of the children (25 of 28 participants). Although not all 
studies regarding the effects of stimulants are in 
agreement, the literature indicates that stimulant 
medications are beneficial for the treatment of ADHD in 
preschool children. 
Although the majority of these studies attest to the 
efficacy of stimulants in preschool children, side effects 
were not systematically evaluated in any these studies and 
several did not report side effects at all. Two studies 
have systematically evaluated side effects of stimulant 
medication in preschool children with ADHD (Barkley et al., 
1985; Firestone, Monteiro-Musten, Pisterman, Mercer & 
Bennett, 1998). The findings from these studies indicate 
that side effects tend to be more common in young children 
and include irritability, nightmares, sleep disturbances 
and alterations in appetite. Although observed more 
frequently in young children, stimulant side effects are 
generally considered to be mild (Barkley, 1985; Connor, 
2002; Firestone, 1998). 
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The Developmental Significance of Play 
In spite of the prevailing attitude that stimulants, 
as used to treat ADHD, are very safe, there is a literature 
regarding their potential adverse effects on the social and 
play behaviors of children that appears to be widely 
overlooked. Basic research has consistently shown that 
drugs such as methylphenidate and amphetamine decrease 
social and play behavior in animals. Additionally, although 
less definitive, a number of clinical studies suggest that 
stimulants can produce significant disturbances in social 
behavior in humans as well.  
This is potentially important because disruption of 
play and social behavior may have serious developmental 
consequences. A major component of wakeful behavior in 
higher mammals from the time of infancy to adulthood is 
social play. Play is thought to provide the first 
expression of many adult behaviors, including sexuality, 
aggressiveness, affiliative behavior and parental behavior 
(Pellis & Pellis, 1990; Poole & Fish, 1976; Taylor, 1980). 
In addition, play may have a significant role in the 
development of motor and sensory skills, language, and 
intelligence (Hofer, 1981).  
Surprisingly, the empirical literature regarding the 
significance of play in children is sparse. Much of what is 
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known about the significance of play comes from basic 
research with animals. Social play in rats displays an 
inverted U-shaped function with respect to age; it emerges 
about 18 days after birth, peaks during the fourth and 
fifth week of life and then declines into adulthood (Meaney 
& Stewart, 1981; Thor & Holloway, 1984; Vanderschuren, 
Niesink & Van Ree, 1997). Researchers have found that the 
opportunity to engage in social play is particularly 
important for normal social development in the rat (Hol, 
Van den Berg, Van Ree & Spruijt, 1999, Van den Berg, Hol, 
Van Ree, Spruijt, Everts & Koolhas, 1999). Deprivation of 
play during the fourth week of life produces serious 
disruptions in normal sexual functioning and agonistic 
behavior, while deprivation during the fifth week of life 
does not appear to produce any significant differences in 
social development (Hol, et al., 1999). These findings 
indicate that there is a critical period in which social 
play may have a particularly important effect on 
development. Einon, Morgan and Kibbler (1978) found that 
rats deprived of social interaction for extended periods of 
time developed normally if allotted brief periods of play 
(i.e. 60 minutes each day), whereas socially isolated rats 
not allowed to play displayed abnormal social functioning. 
This finding suggests that the observed abnormal social 
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development is the result of play deprivation, rather than 
the deprivation of social contact per se.  
A number of studies have investigated the effects of 
social deprivation on the subsequent social development of 
young non-human primates (Mason, 1963; Michael & Zumpe, 
1998; Suomi, 1973; Suomi & Harlow, 1972). Socially deprived 
monkeys exhibit a number of abnormal social behaviors 
including decreased grooming and abnormal play behavior. 
Although no non-human primate studies have specifically 
investigated play, it is possible that deprivation of play 
during periods of social isolation contributes to abnormal 
social development. 
The Effects of Stimulants on Play and Related Social 
Behavior  Basic Research 
 
A number of studies have examined the effects of 
stimulants on play behavior in animals. Without exception, 
these studies show that stimulant drugs significantly 
decrease play behavior. Beatty, Dodge, Dodge, White and 
Panksepp (1982) investigated the effects of stimulant 
medications on a number of social behaviors in rats. 
Specifically, they evaluated the effects of methylphenidate 
(0, 0.5, 2, 4 mg/kg) and d-amphetamine (0, 0.25, 0.5, 1 
mg/kg) on play fighting (instances of boxing, tail-pulling, 
wrestling, pinning, aggressive grooming) and chasing in 
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rats. The researchers found that both drugs significantly 
decreased play fighting in a dose-dependent manner.  
The findings were replicated and expanded in a 
subsequent study by Beatty, Costello & Berry (1984). 
Amphetamine was administered to rats alone and in 
conjunction with a number of other drugs (i.e., 
catecholamine antagonists, agonists and synthesis 
inhibitors). As reported previously, amphetamine (0.5 and 
1.0 mg/kg) significantly decreased the occurrence of play 
behaviors (tail pulling, pouncing, boxing, wrestling, 
pinning, chasing). Interestingly, none of the other drugs 
(i.e., haloperidol, phenoxybenzamine, chlorpromazine, 
propranalol, clonidine, alpha-methyltyrosine) altered the 
play-inhibiting effects of amphetamine. The authors  
concluded that although amphetamine clearly suppresses play 
fighting, the exact mechanism through which it does so is 
unknown. 
Thor & Holloway (1983) evaluated the effects of 
stimulant medication on play-soliciting behaviors in rats. 
The dependent measures used in the experiment included 
darting (running with abrupt stopping) and crossovers 
(climbing over or under the stimulus animal). They found 
that all doses of d-amphetamine (0.5, 1, 2 mg/kg) 
significantly decreased the rate of crossovers and darting 
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and increased the latency to solicit play in a dose-
dependent manner. In addition, all doses of methylphenidate 
(0.5, 1, 2 mg/kg) significantly decreased the frequency of 
crossovers.  
Rats generally exhibit heightened levels of play 
behavior (i.e. pinning, chasing) following periods of 
social deprivation (Beatty, Costello & Berry, 1984). 
Stimulant medications have been shown to block this 
increase in play in a dose-dependent manner (Beatty, 
Costello & Berry, 1984; Beatty et al., 1982, Thor & 
Holloway, 1983). 
The Effects of Stimulants on Related Social Behaviors in 
Rats and Non-Human Primates  
 
Several studies have examined the effects of stimulant 
drugs on social behavior in rats and non-human primates. 
Although many of the dependent variables used in these 
studies are not direct measures of play (e.g., social 
interaction), they are important in that they may be 
considered prerequisites for social play behaviors.  
Gambill and Kornetsky (1976) investigated the effects 
of stimulants on a number of social behaviors in rats. In 
this study, the researchers placed amphetamine treated rats 
in cages with unfamiliar rats. Dependent measures included 
rates of grooming, feeding, sex, sleeping, stereotypy, 
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agonistic behavior and their positioning (i.e., proximal or 
distal) in relation to other rats. Amphetamine (8.0mg/kg) 
significantly decreased the rate at which rats engaged in 
social/agonistic behaviors. In addition, amphetamine-
treated rats tended to remain distal from other rats. 
Arakawa (1994) used a similar paradigm to investigate the 
effects of stimulant drugs on the social behavior of rats. 
Rats were injected with saline, and a range of doses of 
methamphetamine or methylphenidate (0.008 - 5.0 mg/kg). The 
treated rats were then placed in an open field either alone 
or with an untreated rat. It was found that methylphenidate 
at doses of 1.0 mg/kg or greater caused rats to remain 
separate in the field. 
Steinpreis, Sokolowski, Papanikolaou and Salamone. 
(1994) used an intruder paradigm to evaluate the effects of 
stimulant drugs in rats. This paradigm involves placing an 
unfamiliar rat in a cage with an established colony 
containing three other rats. For the purpose of this study, 
the intruder rat was injected with either amphetamine or 
placebo. The researchers found that amphetamine (4.0 mg/kg) 
substantially reduced the occurrence of social behaviors in 
the treated rats, including the number of social threats 
initiated by the intruder rat, the frequency of side 
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mounting, as well as the occurrence of crawling under other 
rats. 
Researchers have also investigated the effects of 
stimulant drugs on the social behavior of nonhuman 
primates. Schlemmer & Davis (1981) found that chronic 
administration of d-amphetamine (3.2 mg/kg daily for 12 
days) significantly increased the number of submissive 
gestures in stumptail macaque monkeys. Thierry Steru, 
Chermat and Simon (1984) evaluated the effects of d-
amphetamine on the greeting behavior of rhesus monkeys. In 
this experiment, the researchers observed the social 
interactions of pairs of d-amphetamine treated juvenile 
rhesus monkeys that had been reunited after a separation of 
two days. Dependent measures included greeting behavior 
(social grooming, social play, and huddling) and frequency 
of presentations and mounts. It was found that that d-
amphetamine (0.1 and 0.2 mg/kg) significantly decreased 
duration of greeting behaviors.   
In another study, Schlemmer, Young and Davis (1996) 
investigated the effects of amphetamine on the social 
behavior of stumptail macaque monkeys. Baseline (no drug) 
observations were conducted on 30 monkeys for 8 days. The 
monkeys were then treated with d-amphetamine (1.6 mg/kg) 
for 12 consecutive days. During amphetamine treatment, 
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monkeys were observed for a 30-second period every five 
minutes during a 60-minute observation session each day. 
Dependent measures included stereotypy, proximity to other 
monkeys, social grooming and submissive behavior. 
Amphetamine produced a number of profound disruptions in 
social behavior, including increased submissive behavior, 
increased stereotypy (specifically self-grooming), and 
decreased social grooming. 
The Effects of Stimulants on Play  Clinical Research  
There has been a considerable amount of clinical 
research concerning the effects of stimulant medications on 
play and related social behaviors in humans. These studies 
can be organized based on whether they examine stimulant 
effects on non-social play, social play, or general social 
behavior. 
Effects on Non-Social Play. Several studies have 
investigated the effects of stimulant medication on non-
social play in humans. To evaluate the effects of 
stimulants on attention span and general activity level, 
researchers often observed children alone in clinic 
playrooms with a variety of toys. Decreases in movement 
(i.e., decreased hyperactivity) and fewer toy exchanges or 
longer duration of toy play (i.e., increased attention 
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span) are usually reported as a positive medication 
response.  
Rapaport, Abramson, Alexander and Lott (1971) observed 
the effects of 10 mg of d-amphetamine on playroom behavior 
in hyperactive children aged 4 to 10. Children were 
monitored in a playroom divided into quadrants. The 
researchers measured the frequency of line crosses (i.e., 
moving to a different quadrant) and general movement as 
measured by actometers. They found that d-amphetamine 
significantly decreased the number of line crosses and 
ankle movement, indicating that locomotor activity was 
suppressed during times of play. Although decreases in 
locomotor activity are considered to be a desired effect of 
stimulant medication, these decreases in general activity 
may have an adverse impact on play.  
Barkley (1977b) examined the effects of 
methylphenidate in 36 hyperactive boys aged 5 to 12 in a 
number of settings. Children were on daily doses ranging 
from 10-30 mg (mean = 18.6). Dependent measures included 
number of vocalizations, the frequency of picking up and 
leaving toys and general activity. In isolated free play 
conditions, it was found that methylphenidate decreased the 
amount of wrist movement, ankle movement, and general 
locomotor activity, indicating that movement during play 
  15
was attenuated. In addition, the authors also noted a 
significant decrease in the number of times medicated 
children switched toys. Again, these findings are presented 
as a positive response to methylphenidate (i.e., improved 
attention span and decreased hyperactivity), yet this 
positive response may have adverse effects on play. 
Barkley & Cunningham (1979a) conducted a study 
investigating the effects of methylphenidate on activity 
level and attention span in a number of settings. 
Participants in this study were 14 hyperactive boys aged 5 
to 12. Prescribed doses of methylphenidate averaged 10.5 mg 
daily. Dependent variables in this study included movement 
as measured with wrist and ankle actometers, duration of 
locomotion, activity changes, the mean time engaged in each 
activity and the number of activities in which they 
engaged. Results showed that methylphenidate significantly 
decreased wrist movement as well as the number of different 
social activities in which treated children engaged. 
Handen, McAuliffe, Janosky, Feldman and Breaux (1995) 
investigated the effects of methylphenidate on 
developmentally disabled children with concurrent diagnoses 
of ADHD during periods of independent play. Two doses of 
methylphenidate (0.3 mg/kg and 0.6 mg/kg) and a placebo 
control were examined in a within-subjects design. 
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Dependent measures included frequency and duration of play 
behavior, physical movement, intensity of play, 
vocalizations, and the frequency of picking up and leaving 
toys. It was found that both doses of methylphenidate 
significantly decreased the intensity of play (i.e., 
vigorous movement during play), the number of 
vocalizations, and the amount of movement during play.  In 
addition, the number of toy pickups and toy leaves 
decreased significantly at the 0.6 mg/kg dose.  
Effects on Social Play. Some studies have specifically 
examined the effects of stimulants on social play in humans 
during interactions between parents and their children with 
ADHD. Cunningham and Barkley (1978) investigated the 
effects of 10 mg of methylphenidate on the mother-child 
interactions of five-year-old hyperactive identical twins 
in a free-play setting. Researchers placed each child in a 
small playroom with their mother and measured wrist and 
ankle movements, the initiation of interactions, the 
frequency of responses, the occurrence of solitary play, 
and mother-directed play among other variables. They found 
that methylphenidate produced a significant decrease in 
sociability for both boys (i.e., decreased social 
interaction and increased solitary play).  
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Barkley & Cunningham (1979b) conducted a similar study 
with twenty children aged 5 to 12. Experimental conditions 
included a no drug condition (neither drug nor placebo), 
placebo, or methylphenidate given at individual prescribed 
doses (mean = 14.6 mg/daily). Dependent measures included 
wrist and ankle movement as measured with actometers, the 
occurrence of mother child interactions, and a parental 
questionnaire. As reported by other researchers, both ankle 
and wrist activity decreased significantly while on 
medication. In addition, children initiated significantly 
fewer social interactions and responded less to their 
mothers while on methylphenidate compared to placebo or no 
drug conditions.   
Effects on Play Related Social Behavior. Several 
studies have examined the effects of stimulants on social 
behavior of preschool children diagnosed with ADHD. 
Although these studies do not specifically investigate 
social play, they are relevant because they examine 
behaviors that may be considered prerequisites for social 
play, such as social interaction.  
Schliefer and colleagues (1975) evaluated the effects 
of methylphenidate in hyperactive preschool children aged 3 
to 5 in unstructured settings. Doses of methylphenidate 
started at 5 mg and then varied depending on observed 
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clinical effects. Children were observed in a nursery 
school setting once each week. Data were taken on specific 
social behaviors (e.g., aggression) during free-play 
settings. Nursery school teachers filled out a three-point 
hyperactivity scale for each participant. The experimenters 
also employed several psychological tests to evaluate the 
effects of methylphenidate (i.e., parts of the Cincinatti 
Test of Preschool Autonomy and the Auditory Continuous 
Performance Test). Additionally, mothers of the children 
attending the program were given the Hyperactivity Rating 
Scale (Werry, 1968). According to parental report, negative 
behaviors (i.e., noncompliance and aggression) occurred 
less frequently while on medication. However, the 
researchers reported that, while receiving methylphenidate, 
most of the children exhibited a variety of negative side 
effects including sleep disturbances, increased solitary 
play, altered mood and decreased social behavior. The 
researchers determined that stimulant-induced adverse 
effects on social functioning were sufficiently severe that 
all but 3 of the 28 participants discontinued use of 
methylphenidate at the conclusion of the study. 
Northup, Gulley, Edwards and Fountain (in press) 
evaluated the behavioral effects of methylphenidate in 
three preschool children aged 4 to 6 in different settings 
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including a preschool classroom and recess. Dependent 
measures used in the classroom included out-of-seat 
behavior, off-task behavior, inappropriate vocalizations, 
and playing with objects. Social engagement was measured 
during recess. Social engagement was defined as initiating 
a social interaction, participating in an interaction, or 
following the rules of an activity. They found that, in 
general, methylphenidate was effective for decreasing many 
disruptive behaviors (i.e. out of seat, inappropriate 
vocalizations, inappropriate object play) in the classroom. 
However, they also found that all doses of methylphenidate 
(0.3 mg/kg, 0.6 mg/kg and 1.0 mg/kg) decreased the 
occurrence of social engagement during recess in a dose-
dependent manner for two of the three children.  
A number of additional studies have documented the 
effects of stimulants on social behavior in school-aged 
children. Rie and colleagues (1975) conducted a study with 
underachieving children aged 7 to 9 using several 
different types of rating scales and achievement tests to 
evaluate the effects of methylphenidate on disruptive 
behavior and academic achievement. The main findings of 
this study were that methylphenidate did not improve 
achievement, but the researchers anecdotally observed a 
number of negative effects of medication on social 
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behavior. The authors stated that, while on medication, 
children, exhibited little or no initiative or 
spontaneity, offered little indication of either interest 
or aversion, showed virtually no curiosity, surprise or 
pleasure and seemed devoid of humor. (p. 258). The authors 
expressed concern regarding the effects of these drug-
induced reductions in responsivity on emotional 
development. It is noteworthy that these children had been 
prescribed relatively low doses of methylphenidate (5 to 20 
mg daily).  
Smith, Pelham, Evans, Gnagy, Molina, Bukstein,  
Greiner, Myak, Presnell & Willoughby (1998) investigated 
the effects of methylphenidate on social behavior in 46 
adolescent children diagnosed with ADHD at a summer 
treatment facility. Dosages used were 10 mg, 20, or 30 mg 
in the morning and at lunch. Participants also received a 
half dose at mid-afternoon (total dosage of methylphenidate 
for the day was either 25, 50, or 75 mg). Dependent 
measures focused mainly on social behavior as determined 
with rating scales completed by counselors and teachers. 
Overall, many participants exhibited improvements in social 
behavior while on low doses of methylphenidate. The authors 
noted, however, that as stimulant dose increased, the 
beneficial effects of stimulants decreased, and the risk of 
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social side effects, including social withdrawal and 
increased listlessness, increased significantly.                  
Stimulant drugs have been shown to produce significant 
disruptions in the social behavior of developmentally 
disabled individuals with ADHD. Helsel, Hersen, Lubetsky, 
Fultz, Sisson & Harlovic (1989) investigated the effects of 
stimulants on behavior in both structured and unstructured 
social settings for four mentally retarded children aged 4 
to 8 with concurrent diagnoses of ADHD. Several dosages of 
methylphenidate were varied for each of the participants, 
with doses ranging from 0.3 to 0.9 mg/kg. Assessment 
procedures included a direct classroom observation during 
academics, performance measures, affect rating measures, 
and teacher rating scales (i.e., Connors Teacher Rating 
Scale). In the classroom observation, dependent measures 
included the occurrence of on-task behavior, in-seat 
behavior, and talking out. Performance measures included 
task accuracy and latency to task completion. As has been 
established in many studies, they found that increasing 
doses of methylphenidate improved on-task behavior.    
Anecdotally, however, they noted a number of dose-related 
negative changes in social behavior for all four 
participants. One participant who was informally evaluated 
for side effects exhibited severe social withdrawal and was 
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described as non-interactive while on the 0.6 mg/kg dose of 
methylphenidate. The researchers did not systematically 
evaluate the stimulant-related side effects in this study.   
Another study with developmentally disabled children 
with concurrent diagnoses of ADHD was conducted by Handen 
and colleagues (1995). Participants were 27 children aged 6 
to 12. The medication conditions in the study included 
placebo and two doses of methylphenidate (0.3 mg/kg and 0.6 
mg/kg). The researchers used a six-point 13-item rating 
scale to determine the presence of side effects in the 
participants. Measures on this scale included, motor 
movements, drowsiness, sadness, staring, moodiness, 
irritability, social withdrawal, anxiety, dizziness, 
stomachaches, headaches, poor appetite, and activity level. 
Although they were unable to detect any consistent pattern 
of behavioral side effects, two subjects exhibited severe 
social withdrawal on the 0.3 mg/kg dose.  
Rationale for the Current Study 
 The primary purpose of the current study was to 
evaluate the effects of stimulant medications on the play 
and social behavior of children during an unstructured 
recess setting, a structured play condition, and an alone 
play condition. Children receiving the extended-release 
stimulant medication, Concerta, were observed an additional 
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time in the afternoon to evaluate its effects over longer 
periods of time. There have been few studies attempting to 
document the effects of stimulant medications in 
unstructured settings. Of the studies including 
observations in unstructured settings, none have 
specifically observed the effects of stimulants on 
behaviors related to social play. 
Another goal in the current study was to investigate 
the effects of stimulant medications on the reinforcing 
properties of social behavior and play by using a 
concurrent-operants reinforcer assessment procedure (i.e., 
Northup, George, Jones & Broussard, 1996; Northup, 
Fusilier, Swanson, Roane & Borrero, 1997) to determine if 
stimulants altered the reinforcing value of play and/or 
social interaction. Given that stimulants have been shown 
to decrease the occurrence of play and related social 
behaviors in rats and non-human primates, it is possible 
that children taking these drugs may be less likely to 
choose social play as a reinforcer.  
There were a number of secondary goals for the present 
study. The first of which was to document the effects of 
stimulants on social behavior in both structured and 
unstructured play settings. It is possible that the 
structured or unstructured nature of the activity may 
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influence the effects of stimulant medication on social 
behavior. Another goal was to document the effects of 
stimulants on play behavior in solitary settings. This 
condition enables comparison between the effects of 
stimulants on behavior in solitary play settings and 
structured and unstructured social play settings. The final 
objective was to evaluate the accuracy of both teachers and 
participants in reporting the presence of side effects. 
This was evaluated with a teacher rating scale, a child 
rating scale and a structured child interview. 
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CHAPTER 2: METHODOLOGY 
Participants and Setting 
Five children between the ages of 4 and 6 participated 
in the current study. All participants were enrolled in the 
Summer Treatment and Research Program (STAR Program) at 
Louisiana State University. Enrollment in the program 
required a prior diagnosis of ADHD based on the criteria of 
the Diagnostic and Statistical Manual for Mental Disorders 
(DSM-IV, American Psychiatric Association, 1994). In 
addition, a consulting psychiatrist provided independent 
confirmation that the children met the DSM-IV criteria for 
ADHD based on parent interviews and scores at least two 
standard deviations above established norms on either the 
ADHD Rating Scale (DuPaul, 1991) or the Connors 
Hyperactivity Scale (Connors, 1973). This study was 
conducted in conjunction with IRB approved medication 
evaluation procedures funded with a NIH grant. 
Response Definitions 
Data were collected for a variety of dependent 
variables across each of the three play conditions (i.e., 
recess, sports training and alone play). Dependent 
variables were defined as follows: 
1) Toy/object play. Defined as any touching of a toy (or 
object) during the interval. 
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2) Solitary play. Defined as engaging in playful activities 
(i.e. toy/object play) without peers for at least five 
seconds during the interval. The appropriateness of the 
play was documented as well. Inappropriate play included 
such behaviors as property destruction. 
3) Social play. Defined as engaging in cooperative 
activities with peers (i.e. throwing a ball back and 
forth, playing games) for at least five seconds during 
the interval. The appropriateness of social play was 
documented as well. Inappropriate social play included 
such behaviors as property destruction, cheating, and 
aggression. 
4) Nonsocial vocalizations. Defined as vocalizations made by 
the child that were not directed at others, such as 
humming or whistling.  
5) Social vocalizations. Defined as vocalizations directed 
at either peers or the recess monitor. Occurrences of 
inappropriate vocalizations, such as name calling or 
complaining, were documented.  
6) High activity level. Defined as the child walking, 
running and/or jumping for at least five seconds of the 
interval.   
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7) Game participation. Defined as the child remaining 
oriented to the game (i.e., looking at the ball) for at 
least five seconds of the interval. 
8) Anxiety/stereotyped behavior. Defined as any instances of 
crying, whining, nail biting, somatic complaints, 
gratuitous hand movements (i.e., hand flapping) or skin 
picking. 
9) Number of escape attempts. Defined as any attempts or 
requests to leave the designated play area. 
10) Social withdrawal. Defined as the child not 
interacting or playing with peers and is at least three 
feet from others for the entire ten second interval.  
11) Steps taken. Defined as the number of steps taken as 
measured with digital pedometers attached to the waist of 
each child. A second pedometer was worn by each child to 
measure the reliability of the instruments.  
Side Effects Measures. Side effects measures were 
completed by the recess monitor/classroom teacher and each 
participant daily. A side effect questionnaire was 
developed from the items from Barkleys Stimulant Drug Side 
Effects Rating Scale (Barkley, 1981). However, items 
specific to play and social behavior were added (See 
Appendices A and B).  
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Self Report Measure.  Summer program staff members 
conducted a brief structured interview for each participant 
while taking each dose of stimulant medication (See 
Appendix C). The self-report measure contained items 
designed to assess if the children understood why they were 
taking the medication and to provide information regarding 
the childs own perception of medication effects. This 
measure represented a qualitative index of the childrens 
perception of medication effects. 
Data Collection and Measurement 
 Data were collected daily for six weeks during the 
summer treatment program. Participants were observed for 
ten-minute periods during unstructured (recess), structured 
(sports training), and alone conditions as described below. 
Each ten-minute observation was divided into 60 ten-second 
intervals. Both partial (i.e., any instance of the behavior 
occurring in the interval) and whole (i.e., instances of 
the behavior lasting for the entire interval) interval 
recording was used for the dependent variables. Partial 
interval data were recorded for most of the dependent 
measures including: toy/object play, solitary and social 
play, social and nonsocial vocalizations, high and low 
activity levels, game participation, escape attempts and 
anxiety behavior. Whole interval recording was used for the 
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measurement of social withdrawal. Frequency data were taken 
for the number of steps taken and were measured with an 
electronic pedometer attached to the waist of each 
participant during all play conditions. The electric 
pedometers approximate the number of steps taken.    
Interobserver reliability data were collected for all 
play conditions in the current study. Observers were 
trained to at least 80% agreement before beginning the 
study. For the recess observations, reliability data were 
collected for 33.3% of sessions. Agreement for the recess 
condition was 84.6% with a range from 50.0% to 100.0% 
across all dependent variables. Agreement was determined by 
taking the number of intervals in which there was agreement 
for all of the variables, divided by the total number of 
possible intervals and then multiplied by 100.  
For the sports training observations, reliability data 
were collected for 36.0% of sessions. Agreement for the 
sports training condition was 85.9% with a range from 66.7% 
to 100.0%.  
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For the alone play observations, reliability data were 
collected for 52.8% of sessions. Agreement for the alone 
play observations was 93.3% ranging from 75.0% to 100.0%.  
Reliability data were collected for 33.8% of the 
sessions in the reinforcer assessment. Agreement for the 
reinforcer assessment was 100.0% for all sessions.  
Procedure 
Unstructured recess. The unstructured recess was a 15-
minute free-play condition conducted outdoors. Recess was 
available to all children attending the summer treatment 
program (n=12), although data were only collected for the 
children participating in the current study. Children were 
restricted to an 80 x 30 foot play area for observations. 
Several common toys were made available for the 
participants to play with (Bouncy Balls, plastic 
trucks/cars, plastic baseball bat, etc.). Observers 
remained outside the designated play area to minimize 
extraneous social contact with the participants. A recess 
monitor (the classroom teacher) was present in the recess 
area to redirect children in cases of immediate harm to 
self or others, or attempts to leave the designated play 
area. Dependent variables for the recess setting included 
toy/object play, social and nonsocial play, social and 
nonsocial vocalizations, activity level, anxiety behavior, 
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escape attempts, social withdrawal and number of steps 
taken. 
Structured Sports Training. The structured sports 
training condition was a behavior management program 
designed to teach sportsmanship and social skills to 
children with ADHD. This program was conducted daily for 
six weeks during the summer treatment program. 
Sportsmanship skills (i.e., clapping, cheering) were 
trained during games of kickball. All children in the 
summer treatment program were involved in the sports 
training program, but for the purpose of the current 
investigation, data were collected for only the six 
participants in this study. Data collectors remained 
outside of the playing area to minimize social contact with 
the children. Dependent variables measured in this 
condition included game participation, social and nonsocial 
vocalizations, high activity level, escape attempts, 
anxiety behavior and number of steps taken. 
Alone play.  Alone play conditions were conducted 
daily for six weeks during the summer treatment program. In 
this condition, the children were placed alone in a room 
with a number of common toys. They were told that someone 
would be back for them in a little while and to do 
whatever they would like. Observers collected data in an 
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adjacent room from behind a two-way mirror. Dependent 
variables for this condition included toy/object play, 
nonsocial vocalization, high activity level, escape 
attempts and number of steps taken.  
Tiger Camp Observations. Due to its extended duration 
of action, children taking the stimulant, Concerta, were 
observed at additional times during Monday, Wednesday, and 
Friday afternoons while attending another summer program. 
The children were observed during play conditions similar 
to the morning recess or sports training conditions. Data 
were not collected on days in which children were not 
engaged in play activities (i.e., arts and crafts). 
Although the onset of behavioral effects for Concerta is 
expected in the same time as the short-acting preparation 
of methylphenidate (within 30 minutes to an hour), peak 
plasma concentrations of Concerta occur six to eight hours 
after administration. Thus, the peak effects occur early in 
the afternoon. Children were observed for ten minutes, as 
was the case in the morning recess and sports conditions. 
The dependent measures in the afternoon observations 
included game participation, social and nonsocial 
vocalizations, activity level, anxiety/stereotyped 
behavior, escape attempts, and social withdrawal.  
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Reinforcer assessment.  A social reinforcer assessment 
was conducted for five of the children during the study. 
Assessment procedures were based on those of Northup, et 
al. (1996) and Northup, et al. (1997). During baseline, 
children were presented with a nonpreferred task (i.e. 
placing blocks in a bucket). The experimenter then 
instructed the participant to place as many or few blocks 
in the bucket as they would like. The average number of 
blocks placed in the bucket during baseline was used as the 
criterion level to earn token coupons in the reinforcer 
assessment condition.  During the assessment condition, the 
participants had to place the criterion number of blocks in 
the bucket to earn one of three coupons for a preferred 
item, including a play alone coupon, a play with 
friends coupon and a quiet time coupon. The children had 
the opportunity to earn as few or as many coupons as they 
would like within a five-minute period. Each play alone 
coupon could be exchanged for the opportunity to play with 
a number of toys in a room alone for two minutes. Each 
play with friends coupon could be exchanged for the 
opportunity to play with a friend for two minutes. Each 
quiet time coupon could be exchanged for the opportunity 
to read, sit in a chair quietly or rest quietly on a couch 
for two minutes. Neither toys nor peers were available to 
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the participant in this condition. Immediately following 
each assessment, children were able to cash in their 
coupons by handing the cards to the experimenter. The type 
of coupon, as well as the order in which they were cashed 
in, were recorded. 
Rating Scales/Child Interview. One teacher rating 
scale for each participant was given to the classroom 
teacher to be completed at the end of each day. The teacher 
was required to complete the questionnaires before leaving 
each day. A child rating scale was administered to each 
participant daily. Additionally, a child interview was 
conducted once while on each dose for each participant 
(i.e., once while on placebo and once for each medication 
dose condition). Both the child rating scale and the child 
interview were conducted in a quiet room with only the 
therapist and child present. 
Medication Status 
 
Participants received one of three previously 
prescribed stimulant medications in this study. A 
consulting child psychiatrist prescribed an alternating 
course of placebo (i.e., sugar pills in capsule form) and 
one dose of either Dexedrine (n=1), Adderall (n=2) or 
Concerta (n=2) for each of the participants. One 
participant received an alternating course of placebo and 
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two doses of Concerta (36 mg and 54 mg). There were two or 
three possible dose conditions for each participant (1 to 2 
medication dose levels and a placebo dose) during the 
experiment. Two participants received Adderall in the 
current study. One participant (Ruby) received 10 mg (0.4 
mg/kg) while another (Eric) received 20 mg (0.8 mg/kg). 
These doses of Adderall were the doses of medication that 
had been prescribed prior to their admission to the summer 
program and are representative of doses that are commonly 
prescribed in clinical practice. One participant (Brad) 
received 20 mg (0.8 mg/kg) of d-amphetamine (Dexedrine). 
This participant had been prescribed this dose of Dexedrine 
before his admission to the summer program. Three 
participants received doses of Concerta. One participant 
(Jack) received 36 mg (1.6 mg/kg) while another (Randy) 
received 54 mg (2.4 mg/kg). The third participant receiving 
Concerta was given two doses: 36 mg (1.6 mg/kg) and 54 mg 
(2.4 mg/kg). For the first two participants receiving 
Concerta, doses used were prescribed before their admission 
to the summer program. The third participant had been 
prescribed 36 mg of Concerta prior to his admission to the 
summer program. During the summer program, the consulting 
psychiatrist increased the dose to 54 mg. Doses of Concerta 
for all participants were doses that are commonly used in 
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clinical practice. With the exception of the director of 
the program, all observers were blind to the medication 
dose. All drug conditions were compared to placebo. The 
director of the program provided the parents with 
instructions each day regarding medication dose for the 
following day. Medication status as well as the time of 
administration, were verbally confirmed with the parents 
each morning.  
Design 
Medication status was alternated daily in a 
multielement single case design (Sidman, 1960) and the 
results were graphed and evaluated via visual inspection 
(Kazdin, 1982). The multielement design was an alternating 
course of treatment (i.e., stimulant medication) and non-
treatment (i.e., placebo) that was rotated in a semi-random 
manner. The alternation of dose conditions was not 
completely random in an effort to have similar numbers of 
observations for each dose condition. The differences 
between dosage levels of each given medication were 
evaluated with a randomization test which randomly assigns 
observations of the dependent variable (e.g., percentage of 
intervals) to the conditions of the independent variable 
(e.g., drug dose or placebo) and then calculates an F-test 
thousands of times until a stable, random distribution of 
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F-tests is created (Edgington, 1996). The F-test produced 
by the actual results of the individual is then compared to 
the randomized F-test distribution to determine the chance 
probability of the actual results. The randomization test 
is well suited for single-subject designs (i.e., 
multielement designs) given that it does not involve many 
of the assumptions for population-based statistical tests  
(i.e., normal distribution, independence of samples). 
To illustrate how the randomization test functions, a 
simple example will be provided. In the current example, 
seven observations are conducted with a given participant. 
Three of the seven observations represent a control 
condition (i.e., placebo) and four represent an experimental 
condition (i.e., stimulant dose). The scores from the 
control condition are 17, 21, and 23 on a given dependent 
variable (i.e., percent of intervals with social 
withdrawal). The scores from the experimental condition are 
22, 25, 25, and 26. If the null hypothesis is true, the 
scores should have an equal probability of being in the 
control or experimental condition. That is, the values are 
interchangeable. The randomization test calculates all 
possible combinations of the 7 observations in one group of 
3 and another group of 4 (there are 35 such arrangements in 
the current example). The relevant test statistic is created 
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for each arrangement, and the statistic obtained is compared 
to that reference distribution (usually referred to as a 
sampling distribution with parametric tests). The null 
hypothesis is then either rejected or retained. In the 
present example, there is only one arrangement of the data 
that would have a smaller mean for control condition and a 
larger mean for the experimental condition. The difference 
obtained in the current example would occur only 2 times out 
of 35, for a probability of approximately .1142.  
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CHAPTER 3: RESULTS 
 
Experiment 1  Unstructured Recess  
Eric. Eric exhibited a significant increase in the 
number of intervals of social vocalizations (from 39.9 to 
58.9% of intervals) while on medication (p<0.01) (See Table 
1 and Appendix D, Figure 4). 
Brad. Brad demonstrated no significant medication 
effects for any of the variables measured during the recess 
condition (See Table 1 and Appendix D). 
Ruby. Ruby exhibited fewer intervals with social 
vocalizations/attempts at social contact while on 
medication during the recess condition (35.2 to 16.0% of 
intervals; p<0.001)(See Table 1 and Appendix D, Figure 4). 
Randy. A significant medication effect was observed 
for toy play during the recess period for Randy. Medication 
significantly increased the number of intervals Randy 
engaged in toy play (76.8 to 91.9% of intervals; p<0.05) 
(See Table 1 and Appendix D, Figure 1). 
Jack. Jack demonstrated no significant medication 
effects for any of the variables measured during the recess 
condition (See Table 1 and Appendix D). 
Rick. A number of significant medication effects were 
observed for Rick during the recess condition at both the 
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low (36 mg) and high (56 mg) Concerta dose. Rick exhibited 
a significant decrease in the number of intervals with toy 
play from 85.0 to 11.0% of intervals while on the high dose 
of Concerta (p<0.001) (See Table 1 and Appendix D, Figure 
1). Additionally, the high dose of Concerta produced a 
decrease in solitary play (51.7 to 3.1%, p<0.001) (See 
Table 1 and Appendix D, Figure 3). The high dose produced a 
decrease in activity level from 59.1 to 14.6% of intervals 
(p<0.001) (See Table 1 and Appendix D, Figure 6). The high 
dose of Concerta produced a significant increase in 
anxiety/stereotyped behavior from 1.3% to 45.6% of 
intervals (p<0.001) (See Table 1 and Appendix D, Figure 7). 
Both doses of Concerta produced significant decreases in 
the occurrence of escape attempts. The high dose of 
Concerta decreased the number of intervals with escape 
attempts from 4.0% to 0.0% (p<0.01). The low dose of 
Concerta decreased the number of intervals with escape 
attempts from 4.0 to 0.0% (p<0.01) (See Table 1 and 
Appendix D, Figure 8). 
Summary. For the recess condition, the findings were 
variable across participants. Both Eric and Ruby exhibited 
significant medication effects for social vocalizations/  
Table 1. Unstructured Recess Observations__________________ 
 
                Eric            Brad            Ruby  
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Dependent          20 mg           20 mg           10 mg 
Variable     Pla    Add     Pla     Dex     Pla     Add____ 
   
 
   
   
   * p<0.05 
  ** p<0.01 
 *** p<0.005 
**** p<0.001 
 
 
 
 
 
Pla = Placebo 
Add = Adderall 
Dex = Dexedrine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1._(continued)                                 ______ 
       
               Randy          Jack             Rick  
Toy  
Play 
64.1% 66.8% 80.0% 69.4% 39.7% 64.0% 
Social  
Play 
81.7% 85.5% 41.5% 51.6% 39.2% 21.3% 
Solitary 
Play 
11.2% 12.0% 45.8% 31.3% 18.3% 44.8% 
Activity 
Level 
18.3% 20.1% 30.5% 43.6% 31.3% 29.3% 
Anxiety 
Behavior 
1.2% 5.2% 2.1% 4.9% 0.0% 0.0% 
Escape 
Attempts 
1.1% 0.2% 0.0% 0.9% 0.8% 0.3% 
Social 
Vocals 
39.9% 58.9% 
** 
22.1% 28.9% 35.2% 16.0% 
**** 
Nonsocial 
Vocals 
0.4% 0.5% 6.4% 7.6% 0.5% 0.3% 
Social 
Withdrawal 
4.4% 0.8% 4.9% 10.1% 15.0% 18.7% 
Steps 
Taken 
608.1 523.1 735.3 705.2 415.4 322.0 
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Dependent         54 mg          36 mg         36 mg  54 mg 
Variable    Pla    Con    Pla     Con    Pla    Con    Con_ 
   
 
 
   * p<0.05 
  ** p<0.01 
 *** p<0.005 
**** p<0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pla = Placebo 
Con = Concerta 
 
 
Toy  
Play 
76.8% 91.9%
* 
73.5% 76.2% 85.0% 78.2% 11.0%
**** 
Social  
Play 
44.0% 45.9% 66.7% 75.8% 40.4% 31.4% 26.6% 
Solitary 
Play 
43.5% 50.5% 17.6% 15.0% 51.7% 52.9% 3.1% 
**** 
Activity 
Level 
29.2% 41.9% 27.2% 32.1% 59.1% 48.1% 14.6%
**** 
Anxiety 
Behavior 
1.2% 3.3% 0.7% 0.2% 1.3% 7.5% 45.6%
**** 
Escape 
Attempts 
12.3% 0.4% 1.8% 1.6% 4.0% 0.0% 
** 
0.0% 
** 
Social 
Vocals 
38.8% 29.1% 47.3% 45.0% 21.9% 15.4% 12.0% 
Nonsocial 
Vocals 
1.2% 3.6% 1.5% 1.6% 7.0% 4.4% 2.0% 
Social 
Withdrawal 
9.8% 11.5% 8.0% 2.5% 12.4% 16.9% 17.6% 
Steps 
Taken 
670.0 670.0 818.5 801.9 595.5 519.2 269.5 
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social interactions. Stimulant dose produced a 46.2% 
increase in the number of intervals with social 
vocalizations for Eric while Adderall produced a 54.5% 
decrease in the number of social interaction/attempts at 
social contact attempts made by Ruby. Randy demonstrated a 
significant 19.7% increase in the number of intervals of 
toy play.  
Rick displayed a number of significant medication 
effects while receiving the high dose of Concerta, 
including an 87.1% decrease in toy play, a 92.2% decrease 
solitary play, a 69.6% decrease in locomotor activity, a 
100.0% decrease in escape attempts as well as significant 
increases in anxiety/stereotyped behaviors (508.0% 
increase). These findings clearly indicate that the high 
dose of Concerta produced a number of detrimental social 
effects for Rick.  
Experiment 2  Structured Sports Training  
Eric. A significant medication effect was observed for 
Eric during the sports training condition. Medication dose 
increased game participation from 82.2 to 94.7% (p<0.05) 
(See Table 2 and Appendix E, Figure 1).  
Brad. Brad exhibited a number of significant 
medication effects during the sports training condition. 
While on medication (20 mg Dexedrine), Brad displayed a 
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significant increase in game participation (56.4% to 84.2% 
of intervals; p<0.001) (See Table 2 and Appendix E, Figure 
1). Medication also produced a significant decrease in 
activity level as measured by the percentage of intervals 
with high activity as well as the number of steps taken. 
During the kickball game, the percentage of intervals with 
high activity decreased from 33.1% to 18.4 % (p<0.01) (See 
Table 2 and Appendix E, Figure 4) while the number of steps 
taken decreased from 842.3 to 375.2 steps (p<0.005) (See 
Table 2 and Appendix E, Figure 7). A mild, but consistent 
increase in anxiety/stereotyped behavior (2.1 to 9.0% of 
intervals) was also observed while Brad was on Dexedrine 
(p<0.005) (See Table 2 and Appendix E, Figure 5). 
Ruby. Ruby demonstrated no significant medication 
effects for any of the variables measured during the sports 
training condition (See Table 2 and Appendix E). 
Randy. Randy exhibited a number of significant 
medication effects during the sports training condition, 
including a significant increase in game participation 
(from 49.9 to 76.0% of intervals; p<0.05) (See Table 2 and 
Appendix E, Figure 1) and a significant increase the number 
of intervals containing anxiety/stereotyped behavior (from 
2.0 to 11.6%; p<0.05) (See Table 2 and Appendix E, Figure 
5). Escape attempts decreased from 16.6 to 1.0% of 
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intervals while on Concerta (p<0.05) (See Table 2 and 
Appendix E, Figure 6). 
Jack. Jack demonstrated no significant medication 
effects for any of the variables measured during the sports 
training condition (See Table 2 and Appendix E). 
Rick. Several significant effects were observed for 
Rick at both the high and low doses of Concerta during the 
sports training condition. Both doses of medication 
produced significant increases in game participation (See 
Table 2 and Appendix E, Figure 1). The low dose of Concerta 
increased participation from 30.4 to 70.0% of intervals 
(p<0.005). The high dose increased game participation from 
30.4 to 86.4% of intervals (p<0.001). Both doses of 
Concerta produced significant decreases in social 
vocalizations during the sports training condition (See 
Table 2 and Appendix E, Figure 2). The low dose decreased 
social vocalizations from 36.0 to 18.6% of intervals 
(p<0.05). The high dose of Concerta decreased social 
vocalizations from 36.0% to 11.6% of intervals (p<0.01). 
Significant increases in anxiety/stereotyped behavior were 
observed for both dose conditions as well (See Table 2 and 
Appendix E, Figure 5). The low dose of Concerta produce an 
increase in the number of intervals of anxiety behavior 
from 6.1% to 31.9% of intervals (p<0.05). The high dose 
  46
increased anxiety behavior from 6.1% to 66.6% of intervals 
(p<0.001). 
Summary. In the sports training condition, a number of 
significant medication effects were observed. Four of the 
six participants demonstrated significant increases in game 
participation (Brad, Randy, Eric and Rick). However, for 
three of these four children, a corresponding increase in 
the amount of anxiety/stereotyped behavior was observed 
while on their prescribed dose of medication (Brad, Randy 
and Rick). Although there did appear to be an increase in 
anxiety behavior for Eric while on Adderall (1.5% to 16.1% 
of intervals), the findings were not statistically 
significant (p=0.06). 
A number of idiosyncratic effects were observed for 
several of the participants in the sports training setting 
as well. For instance, Rick exhibited a significant 
decrease in the number of social vocalizations made during 
the game at both the high and low dose of Concerta (53.2% 
decrease for the low dose and 67.8% decrease for the high 
dose). Brad displayed a significant decrease in locomotor 
activity during the sports training condition.  
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Table 2. Structured Sports Training Observations _ ________ 
 
                 Eric           Brad          Ruby  
 Dependent         20 mg           20 mg           10 mg 
 Variable    Pla    Add     Pla     Dex     Pla     Add____ 
   
 
               Randy          Jack              Rick  
Dependent         54 mg          36 mg         36 mg  54 mg 
Variable    Pla    Con    Pla     Con    Pla    Con    Con_ 
 
 
 
   * p<0.05 
  ** p<0.01 
 *** p<0.005 
**** p<0.001 
 
 
 
Pla = Placebo 
Con = Concerta 
Add = Adderall 
Dex = Dexedrine 
 
Game 
Particptn 
82.2% 94.7% 
* 
56.4% 84.2%
**** 
43.5% 49.0% 
Social 
Vocals 
28.7% 24.4% 26.9% 24.9% 10.5% 7.0% 
Nonsocial 
Vocals 
0.7% 0.9% 18.4% 10.3% 2.5% 0.0% 
Activity 
Level 
10.7% 10.3% 33.1% 18.4%
** 
17.0% 8.3% 
Anxiety 
Behavior 
1.5% 16.1% 2.1% 9.0% 
*** 
0.5% 3.8% 
Escape 
Attempts 
1.2% 0.0% 0.6% 0.5% 6.3% 2.0% 
Steps  
Taken 
346.2 307.6 842.3 375.2
*** 
310.0 196.2 
Game 
Particptn 
49.9% 76.0%
* 
92.3% 95.7% 30.4% 70.0%
*** 
86.4%
**** 
Social 
Vocals 
30.1% 21.5% 36.3% 31.8% 36.0% 18.6%
* 
11.6%
** 
Nonsocial 
Vocals 
2.4% 1.5% 1.0% 2.2% 11.3% 1.8% 0.0% 
Activity 
Level 
19.2% 14.6% 26.5% 22.1% 19.0% 13.8% 8.0% 
Anxiety 
Behavior 
2.0% 11.6%
* 
0.6% 3.4% 6.1% 31.9%
* 
66.6%
**** 
Escape 
Attempts 
16.6% 1.0% 
* 
1.8% 2.5% 9.0% 2.6% 0.6% 
Steps  
Taken 
457.6 236.1 600.3 640.9 233.7 245.5 227.0 
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Experiment 3 - Alone Play  
Eric. Medication dose produced a significant effect on 
locomotor activity in the alone play condition for Eric. 
Adderall decreased activity level from 18.4 to 5.3% of 
intervals (p<0.05) (See Table 3 and Appendix F, Figure 3) 
as well as the number of steps taken from 372.2 to 183.6 
steps (p<0.05) (See Table 3 and Appendix F, Figure 6).  
Brad. Brad exhibited significant medication effects 
during alone play sessions. A significant decrease in 
intervals with vocalizations was observed while Brad was on 
Dexedrine. Vocalizations decreased from 38.0 to 5.9% of 
intervals while on medication (p<0.01) (See Table 3 and 
Appendix F, Figure 2). Additionally, Dexedrine decreased 
the number of steps taken from 187.6 to 105.3 (p<0.05) (See 
Table 3 and Appendix F, Figure 6). 
Ruby. Ruby demonstrated no significant medication 
effects for any of the variables measured during the alone 
play condition (See Table 3 and Appendix F). 
Randy. Randy demonstrated no significant medication 
effects for any of the variables measured during the alone 
play condition (See Table 3 and Appendix F). 
Jack. Jack demonstrated no significant medication 
effects for any of the variables measured during the alone 
play condition (See Table 3 and Appendix F). 
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Table 3. Alone Play Observations         __________________ 
 
                 Eric           Brad           Ruby  
Dependent          20 mg           20 mg           10 mg 
Variable     Pla    Add     Pla     Dex     Pla     Add____ 
   
 
               Randy          Jack              Rick  
Dependent         54 mg          36 mg         36 mg  54 mg 
Variable    Pla    Con    Pla     Con    Pla    Con    Con_ 
   
 
 
   * p<0.05 
  ** p<0.01 
 *** p<0.005 
**** p<0.001 
 
 
 
 
 
 
 
Pla = Placebo 
Con = Concerta 
Add = Adderall 
Dex = Dexedrine 
 
 
 
 
 
Toy  
Play 
97.9% 95.9% 94.8% 97.1% 89.1% 64.5% 
Vocals 
 
3.8% 0.9% 38.0% 5.9% 
** 
20.1% 11.8% 
Activity 
Level 
18.4% 5.3% 
* 
8.5% 4.8% 5.7% 10.0% 
Anxiety 
Behavior 
0.3% 6.0% 0.9% 0.7% 0.4% 0.3% 
Escape 
Attempts 
0.7% 0.6% 0.2% 0.0% 15.1% 5.8% 
Steps 
Taken 
372.2 183.6 
* 
187.6 105.3
* 
128.4 166.2 
Toy  
Play 
99.3% 90.1% 95.5% 88.0% 99.3% 99.9% 99.2% 
 Vocals 
 
33.6% 22.4% 21.9% 10.5% 61.1% 58.6% 52.4% 
Activity 
Level 
9.8% 8.4% 17.3% 29.5% 16.9% 13.0% 2.0% 
Anxiety 
Behavior 
0.0% 0.2% 0.0% 0.0% 0.0% 0.2% 0.6% 
Escape 
Attempts 
0.0% 0.2% 2.3% 1.3% 0.9% 0.2% 0.4% 
Steps 
Taken 
172.8 106.1 359.4 470.1 135.2 247.7 341.8 
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Rick. Rick demonstrated no significant medication 
effects for any of the variables measured during the alone 
play condition (See Table 3 and Appendix F). 
Summary. Relatively few significant medication effects 
were observed in the alone play condition. Two of the six 
participants demonstrated significant decreases in 
locomotor activity while taking their prescribed dosage of 
medication. For Eric, both the number of intervals of high 
activity and the number of steps taken decreased 
significantly while taking Adderall. For Brad, the number 
of steps taken during alone conditions decreased as well. 
Another idiosyncratic finding was the decrease in the 
number of vocalizations made by Brad while on Dexedrine.   
Experiment 4  Tiger Camp Observations 
Randy. Randy displayed higher levels of game 
participation while on medication (45.0% to 86.0% of 
intervals, 91.1% increase) during the Tiger Camp 
observation (See Table 4 and Appendix G, Figure 1). 
Additionally, higher levels of anxiety/stereotyped behavior 
were observed while on medication (7.0% to 22.0% of 
intervals, 214.3% increase) for Randy (See Table 4 and 
Appendix G, Figure 5). 
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Table 4. Tiger Camp Observations         __________________ 
 
               Randy          Jack              Rick  
Dependent         54 mg          36 mg         36 mg  54 mg 
Variable    Pla    Con    Pla     Con    Pla    Con    Con_ 
   
 
Pla = Placebo 
Con = Concerta 
Add = Adderall 
Dex = Dexedrine___________________________________________ 
 
 
 
Jack. Jack demonstrated no significant medication 
effects for any of the variables measured during the Tiger 
Camp observations (See Table 4 and Appendix G). 
Rick. Rick displayed higher levels of game 
participation while on medication (an increase from 78.5% 
on placebo to 100.0% for both the low and high dose, 24.7% 
increase) (See Table 4 and Appendix G, Figure 1).  
Summary. In summary, there were relatively few 
significant findings for the Tiger Camp observations. 
Additionally, the findings that were significant must be 
interpreted with caution due to the limited number of
Game 
Particptn 
45.0 86.0 60.0 100.0 78.5 100.0 100.0 
Social 
Vocals 
3.0 18.2 13.5 27.7 3.5 9.0 8.0 
Activity 
Level 
15.0 19.2 16.7 21.3 15.0 21.5 3.0 
 
Anxiety 
Behavior 
7.0 22.0 3.0 1.0 44.0 19.0 42.0 
Escape 
Attempts 
0.0 0.0 0.0 0.0 17.5 0.0 0.0 
 
Social 
Withdrawal 
0.0 1.0 0.0 0.0 0.0 0.0 0.0 
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observations conducted. Due to the limited number of 
observations, statistical tests could not be conducted. 
Experiment 5  Social Reinforcer Assessment  
Eric. Significant medication effects were observed 
during the social reinforcer assessment for Eric. He 
selected a greater proportion of peer play coupons while 
taking Adderall (83.3% as compared to 71.8%). In addition, 
the number of alone play coupons selected decreased while 
on Adderall (28.2% to 16.7%). Eric selected fewer total 
coupons (3.9 as compared to 3.0) while taking the 
prescribed dose of medication  (See Table 5 and Appendix H, 
Figures 4 and 5). 
Brad. Significant medication effects were observed in 
the social reinforcer assessment for Brad. He displayed a 
significant decrease in number of peer coupons selected 
while taking Dexedrine (86.5% to 63.9%). In addition, a 
corresponding increase in the number of quiet time coupons 
selected (8.1% to 27.8%) was observed while he was on 
medication  (See Table 5 and Appendix H, Figure 5). 
Randy. Some minor medication effects were observed 
during the social reinforcer assessment for Randy. Concerta 
decreased the percentage of peer coupons selected from 
100.0% to 90.5%. Medication dose also produced a slight 
increase in the amount of alone and quiet coupons selected 
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(from 0.0% to 2.4% for alone coupons and from 0.0% to 7.1%, 
respectively) (See Table 5 and Appendix H, Figure 5).  
Jack. No significant medication effects were observed 
for the type of coupons selected by Jack during the 
reinforcer assessment. The total daily number of coupons 
selected by Jack increased from 3.5/day to 4.9/day (a 40.0% 
increase) while on Concerta (See Table 5 and Appendix H, 
Figure 4).  
Rick. Rick exhibited a number of significant 
medication effects during the social reinforcer assessment. 
Rick selected significantly fewer peer coupons while on the 
high dose of Concerta (67.7% to 40.0% of coupons). 
Furthermore, a corresponding increase in alone play coupon 
selection was observed while Rick was on the high dose of 
Concerta (32.3% to 53.3% of coupons). Peer play coupons 
were selected at the highest rate while on the low dose of 
Concerta (86.7%). Additionally, alone coupons were selected 
at the lowest rate while on the low medication dose (13.3%) 
(See Table 5 and Appendix H, Figure 5). 
Summary. A number of significant medication effects 
were observed during the social reinforcer assessment. Brad 
and Rick exhibited pronounced decreases in the number of 
peer play coupons selected while on the high dose of 
medication. The number of peer play coupons selected by 
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Brad decreased by 28.1% while taking his prescribed dose of 
Dexedrine. The number of peer play coupons selected by Rick 
decreased by 42.9% while taking the high dose of Concerta. 
Additionally, a corresponding increase in the number of 
alone play coupons (Rick) or quiet time coupons (Brad) was 
observed. The number of alone play coupons selected by Rick 
increased from 1.0 to 1.6 (60.0% increase) at the high dose 
of Concerta. Brad displayed an increase in the number of 
quiet time coupons while taking Dexedrine (0.3 to 1.0 
coupons daily, 233.3% increase). Another participant 
(Randy) appeared to exhibit a mild decrease in the number 
of peer play coupons while on medication (4.3 to 3.8 
coupons daily, 11.6% decrease).  
One participant (Eric) selected more peer play coupons 
while receiving his prescribed dose of medication. In 
addition, a corresponding decrease in the number of alone 
play coupons was observed while taking Adderall. These 
findings indicate that, for Eric, stimulant medication may 
have increased the reinforcing value of social play.  
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Table 5. Social Reinforcer Assessment Results   _ _ _______ 
 
              Eric             Brad            Randy  
Dependent        20 mg             20 mg           54 mg 
Variable   Pla    Add      Pla      Dex     Pla     Con____ 
   
 
 
             Jack                       Rick  
Dependent          36 mg                36 mg      54 mg 
Variable   Pla      Con       Pla        Con        Con____     
   
 
 
Pla = Placebo 
Con = Concerta 
Add = Adderall 
Dex = Dexedrine 
 
 
 
 
 
 
Peer 
Play 
2.8 
(71.8%) 
2.5 
(83.3%) 
3.2 
(86.5%)
2.3 
(63.9%) 
4.3 
(100%) 
3.8 
(90.5%)
Alone 
Play 
1.1 
(28.2%) 
0.5 
(16.7%) 
0.2 
(5.4%) 
0.3 
(8.3%) 
0.0 
(0.0%) 
0.1 
(2.4%) 
Quiet 
Time 
0.0 
(0.0%) 
0.0 
(0.0%) 
0.3 
(8.1%) 
1.0 
(27.8%) 
0.0 
(0.0%) 
0.3 
(7.1%) 
Total 3.9 
(100%) 
3.0 
(100%) 
3.7 
(100%) 
3.6 
(100%) 
4.3 
(100%) 
4.2 
(100%) 
Peer 
Play 
3.5 
(100%) 
4.9 
(100%) 
2.1 
(67.7%) 
1.3 
(86.7%) 
1.2 
(40.0%) 
Alone 
Play 
0.0 
(0.0%) 
0.0 
(0.0%) 
1.0 
(32.3%) 
0.3 
(13.3%) 
1.6 
(53.3%) 
Quiet 
Time 
0.0 
(0.0%) 
0.0 
(0.0%) 
0.0 
(0.0%) 
0.0 
(0.0%) 
0.2 
(6.7%) 
Total 3.5 
(100%) 
4.9 
(100%) 
3.1 
(100%) 
1.6 
(100%) 
3.0 
(100%) 
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Teacher Rating Scale  
Eric. No significant medication effects were noted for 
Eric on any of the variables from the teacher rating scale 
(See Table 6). 
Brad. The teacher scale indicated that Brad was less 
euphoric/unusually happy (p<0.05) and played alone more 
frequently while taking medication (p<0.05) (See Table 6). 
Ruby. A number of significant medication effects were 
observed for Ruby on the teacher rating scale. According to 
teacher report, Ruby stared more and daydreamed more 
frequently (p<0.05), interacted less with others (p<0.05), 
exhibited increased drowsiness (p<0.005), appeared more 
sad/unhappy (p<0.05), was less playful with others 
(p<0.01), played alone more on medication (p<0.01) and 
appeared more socially withdrawn while on Adderall (p<0.05) 
(See Table 6).  
Randy. On the teacher rating scale, a number of 
significant medication effects were reported for Randy. 
Randy was reported to stare and daydream more frequently 
while on Concerta (p<0.05). The teacher also reported that 
Randy appeared to be less anxious (p<0.05), less euphoric 
or happy (p<0.01) and played alone less while on medication 
(p<0.01) (See Table 6). 
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Jack. No significant medication effects were noted for 
any of the variables from the teacher rating scale (See 
Table 6). 
Rick. No significant medication effects were noted for 
any of the variables from the teacher rating scale (See 
Table 6). 
Summary. The findings from the teacher rating scales 
are especially interesting given that they did not appear 
to correspond with direct observations from the other 
phases in the current investigation. It is of particular 
interest that the child exhibiting the most pronounced 
social side effects in the direct observations (Rick) had 
no significant behavioral side effects indicated on the 
teacher rating scale. 
Additionally, it is notable that the lowest 
functioning child (Ruby) had the highest ratings for 
medication side effects. According to teacher report, Ruby 
exhibited a number of detrimental social side effects while 
taking Adderall (e.g., low levels of social play, increased 
social withdrawal, increased unhappiness). Again, these 
findings did not correspond well with the results from the 
direct observations.  
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Table 6. Teacher Rating Scale Results______________________              
 
                     Eric          Brad           Ruby  
 Dependent              20 mg          20 mg          10 mg 
 Variable        Pla    Add     Pla    Dex     Pla    Add _ 
 
1. Daydreams 0.9 0.8 0.6 1.7 1.33 4.2* 
2. Talks less  1.6 1.4 1.4 2.2 1.5 4.4* 
3. Uninterested 1.1 1.1 1.1 2.0 1.83 3.2 
4. Appetite n/a n/a n/a n/a n/a n/a 
5. Irritable 1.2 1.4 2 1.9 1.5 1.2 
6. Stomachaches 0 0 0 0 0 0 
7. Headaches 0 0 0 0 0 0 
8. Drowsiness 0 0 0 0.3 0.33 3.6***
9. Sad/unhappy 0.2 0.7 1 1.0 0.67 2.8* 
10. Cry/whine 1.0 1.1 1.5 1.1 1.67 1.8 
11. Anxious 1.5 1.7 1.8 2.5 1.83 1.4 
12. Fingernails 0 0 0 0 0 0 
13. Euphoric 3 2.4 3.1 1.3* 4.5 1.8 
14. Dizziness 0 0 0 0 0 0 
15. Tics  0.4 0.3 0 0 0.17 0 
16. Playful  6.8 6.3 6.1 5.1 4.67 2.2** 
17. Play alone 2 2.5 2.4 4.0* 4.5 7.2** 
18. Withdrawn 1.6 1.8 1.8 1.9 2.83 5.4* 
19. Nail biting 0 0 0 0 0 0 
20. Skin pick 0 0 0 0 0 0 
 
 
   * p<0.05 
  ** p<0.01 
 *** p<0.005 
**** p<0.001 
 
 
 
 
Pla = Placebo 
Add = Adderall 
Dex = Dexedrine 
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Table 6._(continued)                             __________ 
 
                   Randy         Jack             Rick  
Dependent             54 mg         36 mg        36 mg  54 mg 
Variable         Pla   Con    Pla    Con    Pla   Con    Con_ 
   
1. Daydreams 0.7 1.6* 0.8 1.0 2.4 2.0 1.7 
2. Talks less  1.6 2.0 1.7 1.8 3.6 3.2 2.0 
3. Uninterested 2.1 1.7 2.1 1.4 3.6 3.8 2.3 
4. Appetite n/a n/a n/a n/a n/a n/a n/a 
5. Irritable 1.0 1.3 4.1 2.6 2.6 2.1 1.3 
6. Stomachaches 0 0 0 0 0 0 0 
7. Headaches 0 0 0 0 0 0 0 
8. Drowsiness 0 0 0 0 0.3 0.9 0.7 
9. Sad/unhappy 0.6 0.4 3 2.1 1.9 1.6 1.3 
10. Cry/whine 1.4 1 3.9 2.8 2 1.6 1.7 
11. Anxious 2.1 0.7* 4 2.3 1.6 1.7 1.7 
12. Fingernails 0 0 0 0 0 0 0 
13. Euphoric 4.6 1.8** 2.5 1.3 3.1 1.7 1.0 
14. Dizziness 0 0 0 0 0 0 0 
15. Tics  0.1 0 0.3 0.1 0.9 0.5 0 
16. Playful  5 5.92 6.4 7 3.4 3.8 4.0 
17. Play alone 4.8 2.8** 2.6 2.1 6.4 5.5 6.0 
18. Withdrawn 2.3 1.6 2.3 1.4 4.1 3.8 3.7 
19. Nail biting 0 0 0 0 0 0 0 
20. Skin pick 0 0 0 0 0 0 0 
 
   * p<0.05 
  ** p<0.01 
 *** p<0.005 
 
Pla = Placebo 
Con = Concerta
**** p<0.001 
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Child Rating Scale  
Eric. No significant medication effects were noted for 
any of the variables for Eric on the child rating scale 
(See Table 7). 
Brad. While on his prescribed dose of Dexedrine, Brad 
indicated that he felt less nervous while taking medication 
(p<0.05). No other variables from the child rating scale 
were significant (See Table 7).  
Randy. No significant medication effects were noted 
for any of the variables from the child rating scale (See 
Table 7).  
Ruby. Given her communication difficulties (i.e., 
selective mutism), the child rating scale was not 
administered to Ruby. 
Jack. No significant medication effects were noted for 
any of the variables from the child rating scale (See Table 
7). 
Rick. On the child rating scale, Rick reported that it 
was more difficult for him to have fun while receiving the 
placebo dose (p<0.05) (See Table 7). 
Summary. Only two significant findings were reported 
with the child rating scale. Brad reported that he felt 
less nervous while taking Dexedrine. Nick reported that it 
was more difficult to have fun while on the placebo dose.  
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Table 7. Child Rating Scale Results______________________                
 
                     Eric          Brad           Randy  
   Dependent           20 mg          20 mg          10 mg 
   Variable      Pla    Add     Pla    Dex     Pla    Add _ 
 
1. Somatic 
complaints 0 0 0 0.2 0.1 0.1 
2. Talk to 
other kids  2.0 2.0 0.1 0 0.3 0.5 
3. Pay 
attention  0.4 0 0 0 0.1 0 
4. Stay quiet  0.7 0.5 0 0.2 0 0 
5. Tired  0.7 0.5 1.4 0.8 0.6 0.2 
6. Sad  0.7 0.3 0.1 0 0.4 0 
7. Nervous  0.4 0.3 0.4 0* 0.3 0 
8. Happy  1.9 1.8 2.0 1.9 1.3 1.4 
9. Stay in your 
seat 0.4 0 0.4 0 0.3 0 
10. Dizzy  1.1 0.5 0.2 0.2 0.6 0.3 
11. Play with 
friends  1.8 1.8 1.8 2.0 1.5 1.4 
12. Easy to do 
work 1.9 2.0 2.0 2.0 1.5 1.6 
13. Easy to be 
good  1.7 1.8 2.0 2.0 1.3 1.6 
14. Slow  1.0 0.5 0.4 0.4 0.6 0.4 
15. Hard to 
have fun  0.6 0.3 0.3 0.4 0.3 0.4 
 
 
   * p<0.05 
  ** p<0.01 
 *** p<0.005 
**** p<0.001 
 
 
 
 
Pla = Placebo 
Add = Adderall 
Dex = Dexedrine 
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Table 7. _(continued) ____                            _____ 
 
                      Jack                  Rick  
Dependent                 36 mg            36 mg   54 mg 
Variable           Pla     Con     Pla      Con     Con   _ 
   
1. Somatic 
complaints 0.3 0 1.2 1.3 2.0 
2. Talk to other 
kids  0.5 0.4 1.2 1.3 1.5 
3. Pay attention 0 0.2 1.2 1.8 2.0 
4. Stay quiet  0 0.2 1.2 1.5 2.0 
5. Tired  0.2 0.2 1.6 1.5 2.0 
6. Sad  0.2 0 0.8 1.0 1.0 
7. Nervous  0 0.2 1.2 1.3 2.0 
8. Happy  1.5 1.2 1.6 1.8 2.0 
9. Stay in your 
seat 0.2 0 2.0 1.8 2.0 
10. Dizzy  0 0 1.2 1.5 2.0 
11. Play with 
friends  1.0 0.9 1.6 1.8 1.5 
12. Easy to do 
work 0.3 0.7 1.6 1.2 2.0 
13. Easy to be 
good  0.3 0.7 2.0 1.8 2.0 
14. Slow  0.2 0 1.6 1.0 2.0 
15. Hard to 
have fun  0.17 0.2 2.0 0.8* 1.0 
     
   
   * p<0.05 
  ** p<0.01 
 *** p<0.005 
**** p<0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pla = Placebo 
Con = Concerta 
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No other significant findings were reported by any of the 
participants.    
Structured Child Interview  
Eric. While taking medication, Eric reported that he 
did not like the way it made him feel. While receiving the 
placebo dose, Eric reported that he liked the way his 
medication made him feel. 
Brad. While on Dexedrine, Brad reported that he would 
stop taking his medication if given the opportunity. 
Conversely, while on the placebo dose, Brad reported that 
he would not stop taking his medication if given the 
chance. 
Randy. While on Concerta, Randy reported that he would 
stop taking his medication if given the opportunity.  
Ruby. Given her communication difficulties (i.e., 
selective mutism), the child interview was not used with 
Ruby. 
Jack. No significant medication effects were noted for 
any of the variables from the child interview. 
Rick. No significant medication effects were noted for 
any of the variables from the child interview. 
Summary. Similar to what was seen with the child 
rating scale, the children appeared to have difficulty 
answering questions regarding their medication effects 
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accurately during the structured interview. The only 
relatively consistent finding was that three of the 
children (Brad, Randy and Eric) reported that they did not 
like the way medication made them feel while they were 
taking their prescribed dose of stimulant medication.  
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CHAPTER 4: DISCUSSION 
The purpose of the current investigation was to 
determine if stimulant medications alter play and related 
social behavior in preschool children diagnosed with ADHD. 
To evaluate these effects, a number of measurement 
techniques were employed, including direct observations of 
social behavior in a variety of different play conditions 
(recess, sports training, alone play and Tiger Camp 
observations), an evaluation of the reinforcing efficacy of 
play with a social reinforcer assessment and child and 
teacher rating scales/child interviews. 
The findings from the recess observations illustrate 
the variability in medication response across participants. 
With the exception of Rick, relatively few significant 
findings were ascertained in the recess observations. Rick 
exhibited a number of pronounced medication effects while 
on the high dose of Concerta (54 mg), including decreased 
toy play, decreased solitary play, decreased activity level 
and increased levels of anxiety/stereotyped behavior.  
There were some other idiosyncratic effects during the 
recess observations for two of the participants. Ruby 
exhibited a significant decrease in the number of social 
vocalizations while taking Adderall. Conversely, Adderall 
increased the occurrence of social vocalizations made 
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during the recess period for Eric. The fact that the exact 
opposite effects were observed on the same dependent 
measure for two different participants illustrates the high 
degree of variability in the individual response to 
stimulant medications.  
The purpose of the sports training condition was to 
determine if stimulant medications have significant effects 
on social behavior during structured play settings. In this 
condition, stimulant medication significantly increased 
game participation for several of the participants while 
producing a corresponding increase in anxiety/stereotyped 
behavior. With the exception of one participant (Rick), the 
increase in anxiety/stereotyped behavior was observed 
specifically in the structured sports training setting and 
in neither unstructured play conditions (recess and alone 
conditions). Rick exhibited heightened levels of 
anxiety/stereotyped behavior, including lip picking and 
nail biting, in both the sports training and the 
unstructured recess conditions. Similar kinds of stimulant-
induced stereotyped behaviors have previously been 
documented in humans and have been referred to as punding 
(Fernandez & Friedman, 1999; Schiorring, 1981). According 
to Schiorring (1981), punding includes motor stereotypy 
with repetitive, aimless activities involving various 
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objects, including ones own body (e.g., hands and mouth). 
Given the status of the current literature, the 
improvements in game participation were expected and would 
generally be considered beneficial. Conversely, the effects 
of stimulant-induced anxiety/stereotyped behavior are 
unknown and present a new avenue for future research. 
The purpose of the alone play condition was to 
evaluate the effects of stimulant medication on behavior in 
an unstructured, nonsocial play setting. Again, the 
findings from the alone play condition demonstrate the high 
variability in individual medication response. Two of the 
children exhibited minor decreases in locomotor activity 
(i.e., activity level and/or steps taken) while taking 
stimulant medication. This finding is consistent with 
previous research documenting stimulant-induced decreases 
in locomotor activity (Barkley & Cunningham, 1979a; Barkley 
& Cunningham, 1979b; Cunningham & Barkley, 1978; Handen, et 
al., 1995). Another participant exhibited a significant 
decrease in the occurrence of vocalizations while on 
stimulant medication.   
The findings from the reinforcer assessment indicated 
that stimulant medication significantly altered the 
reinforcing value of specific types of play for several of 
the participants. Stimulant medication decreased the 
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reinforcing value of social play while increasing the value 
of solitary play (Rick) or quiet time (Brad) for two of the 
participants. Stimulant medication had the opposite effect 
for another participant (Eric). For this participant, 
social play appeared to increase in value while on 
stimulant medication. As had been observed in the direct 
observations, the findings from the reinforcer assessment 
indicate that the social effects of stimulant medication 
can vary significantly across individuals. 
The rating scales and child interview were designed to 
determine if indirect measures were useful for detecting 
social side effects and if these measures correlated well 
with direct observations. The measures used in this 
evaluation included a teacher rating scale, a child rating 
scale and a structured child interview. Overall, the data 
from the rating scales and interview did not correlate well 
with direct observations or the social reinforcer 
assessment. The child exhibiting the most pronounced side 
effects in direct observations (i.e., Rick) had no 
significant behavioral side effects indicated on any of the 
variables from the teacher rating scale. Another 
participant (i.e., Ruby) was reported to have a number of 
social side effects that were not observed in the direct 
observations. 
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Additionally, the participants from the study were 
unable to reliably report their own side effects with the 
daily child rating scale and a structured interview. It is 
possible that preschool children are too young to 
accurately report how medication makes them feel. 
The present findings show that stimulants can have 
detrimental effects in some children. The prevailing 
opinion is that stimulant medications either have no 
significant detrimental effects on social behavior (Dulcan 
& Benson, 1997; Hinshaw, 1991; MTA Cooperative Group, 2000; 
NIH Consensus Statement, 1998), or improve it (Granger, 
Whalen & Henker, 1993; Smith, et al., 1998; Pelham, 
Greenslade, Vodde-Hamilton, Murphy, Greenstein, Gnagy, 
Guthrie, Hoover & Dahl 1990, Klein, 1993). One possible 
reason for this apparent contradiction is that some 
observers may mistakenly perceive the absence of disruptive 
behavior as an improvement in adaptive behavior. As is done 
with other disorders (e.g., schizophrenia), it is possible 
to conceptualize the symptoms of ADHD as being either 
positive or negative. Positive symptoms are undesired 
behaviors, such as inappropriate vocalizations or out-of-
seat behavior in the classroom. As reviewed previously, 
stimulants have been shown to be quite effective for 
reducing the occurrence of such symptoms (Greenhill, 
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Halperin & Abikoff, 1999; Pelham, 1993). Negative symptoms 
are behaviors that are desired, yet deficient, such as 
academic achievement and prosocial behavior. Stimulants 
have not been shown to be effective for improving the 
negative symptoms associated with ADHD (i.e., Rie et al., 
1975). A possible explanation for conflicting views about 
the efficacy of stimulants in improving social behaviors in 
ADHD is that they reduce positive symptoms by decreasing 
social interaction and play.   
The results from the current study illustrate the high 
degree of individual variability in medication response 
across participants. Medication had a number of detrimental 
social effects in some participants while other children 
displayed improvements in social behavior (i.e., social 
interaction). These findings demonstrate the utility of 
single subject research for clinical medication evaluation.   
Another important contribution from the current study 
was the finding that stimulant medication can significantly 
alter the reinforcing efficacy of social play. Stimulant 
medication decreased the value of social play for some 
children, while it increased its value for another. These 
findings are of particular importance given that they 
illustrate how stimulants influence the motivation to 
engage in particular activities, including social play. The 
                          
 71
implications of these results are that stimulant 
medications can significantly affect the reinforcing 
properties of certain items and/or activities, which can 
therefore influence the effectiveness of behavioral 
interventions.  
Another important finding from the current study was 
the lack of correspondence between direct observations and 
the results from the rating scales and child interview. 
Given that most medication changes are based on anecdotal 
report and/or rating scale data, this lack of agreement is 
of great significance. The results from this investigation, 
specifically the teacher rating scale, raise a number of 
questions regarding the validity of rating scales. There is 
a need for research investigating the characteristics that 
make side effects for some children more likely to be 
noticed than in others. It is possible that side effect 
detection varies as a function of time spent with the 
child. It is also likely that children who are disruptive 
tend to be observed more closely by teachers and parents.  
The current investigation presented some unique 
methods for assessing the value of social play in children. 
Direct observations, although logically appealing, are 
rarely used in the context of medication assessments. The 
observation procedures used in this investigation may 
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provide researchers with a useful resource for assessing 
the social effects of psychotropic medication. 
Additionally, the social reinforcer assessment 
presented a unique way to evaluate the effects of 
psychotropic medication on the value of social reinforcers. 
The reinforcer assessment provided useful insight regarding 
the effects of these medications and required very little 
time to conduct. The results from the current study 
demonstrate that reinforcer assessments can be used as an 
effective medication assessment tool.   
The current study was also unique in that it included 
a number of supplemental self-report measures. There has 
been little research investigating the use of such measures 
in young children. Although the reliability of child self-
report was questionable in the current study, it indicated 
that it is an area that requires further investigation. 
Limitations in the Current Study 
There were a number of limitations in the current 
investigation. The first of which was the limited number of 
dose conditions for each participant in the study. With the 
exception of Rick, only two dose conditions were used for 
each child (i.e., placebo and one drug dose). A greater 
number of significant social effects may have been observed 
had higher doses been used for some of the participants. 
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Several of the children in the current study were 
prescribed relatively low doses of stimulant medication. 
Another limitation in the current study was the 
difficulty having an equal number of observations for each 
medication condition. Due to absences, clinical necessity 
and time constraints, it was not possible to have an equal 
number of observations for each medication condition.  
Another constraining factor in this investigation was 
the limited amount of reinforcers (i.e., coupons) available 
during the reinforcer assessment. The coupons used in the 
current assessment were redeemable for 2 minutes of the 
preferred activity (social play, alone play or quiet time). 
Due to time constraints during the day, the total number of 
coupons that could be redeemed was limited. Due to this 
ceiling effect, the sensitivity of the assessment may have 
been limited.  
Future Directions 
The current investigation indicates that there are a 
number of areas in need of further research. First, there 
is a need to place greater emphasis on the inclusion and 
measurement of play and social behaviors in future 
evaluations of stimulant medication effects. The majority 
of previous research has emphasized the effects of 
stimulant drugs on maladaptive behavior. Effects on 
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adaptive, particularly prosocial behavior and play, need to 
be studied as well. This is particularly important 
considering the central role that such behavior is assumed 
to play in normal development.  
Second, there is a need for the development of 
objective medication evaluation procedures that can be used 
in a wide variety of settings. As has been previously 
discussed, medication evaluation procedures are frequently 
limited to anecdotal report and rating scales. A number of 
basic behavioral methodologies, such as direct observation, 
functional analyses and reinforcer assessments, may provide 
researchers with useful tools for the objective evaluation 
of medication effects (Fisher, Piazza, Bowman, Hagopian, 
Owens & Slevin, 1992; Iwata; Dorsey, Slifer, Bauman & 
Richman, 1994; Northup, et al., 1996).  
Third, there is a need for pharmacological research 
with young children. As discussed previously, there is a 
considerable amount of literature indicating that the 
adverse social effects of stimulant drugs occur at an 
especially high rate in young children (Firestone, et al., 
1996; Northup, in press; Schliefer, et al., 1975). Given 
this and the fact that use of stimulant drugs in this 
population is off label (stimulants have been approved for 
use in children aged 7 or older), use of stimulants in 
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preschool children is becoming a central issue.  Also 
needed are more studies of the long-term efficacy and side 
effects from the use of these medications. 
Summary and Conclusions 
It is widely accepted as axiomatic that play and 
social interaction are important to normal childhood 
development. The present study highlights a number of 
potentially useful techniques for assessing the social 
effects of stimulants in children. Although numerous 
studies have evaluated the social effects of stimulant 
medication, in many of these studies social behavior and 
play have been peripheral considerations, and therefore not 
studied thoroughly, systematically, and with methodologic 
rigor.  Second, the clinical literature suggests that the 
behavioral effects of stimulants, including those on social 
behavior and play, are highly idiosyncratic (Handen, et 
al., 1995, Northup, et al., in press; Rapaport, et al., 
1994; Whalen, Henker, Swanson, Granger, Kliewer & Spencer, 
1987).  Reliance on group designs, which is the norm in 
psychopharmacology research, as opposed to single subject 
designs, tends to obscure such individual differences.  
Third, there has been an over-reliance on rating scales and 
clinical impressions for determining the presence of the 
adverse effects of psychotropic medications. Although 
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useful, rating scales have a number of limitations for the 
evaluation social and play behaviors. In addition to rater 
bias and possible halo effects, most current rating scales 
focus almost exclusively on the core symptoms of ADHD 
(i.e., attention, hyperactivity and impulsivity) and/or 
disruptive classroom behavior rather than social behavior. 
It is noteworthy that the most commonly used rating scale 
for ADHD has only one question that is generally related to 
social behavior.    
In conclusion, stimulants are now being administered 
to children on an unprecedented scale. Although serious 
problems affecting high percentages of children have not 
been detected despite decades of use, medical history has 
shown, sometimes tragically (e.g., in the case of 
thalidomide), that drugs can have hidden dangers. Given the 
vulnerability of the principal patient population and the 
scale on which these drugs are being used, any hint of risk 
should be given serious consideration.   
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APPENDIX A - CHILD RATING SCALE 
 
 
Side Effect Rating Scale 
Child Form 
 
1. My head/stomach hurts 
today (or any other 
somatic complaints). 
2. I didnt feel like 
talking to other kids 
today 
3. It was hard to pay 
attention today 
4. I had a hard time 
staying quiet today 
5. I feel tired today 
 
6. I feel sad today 
 
7. I feel nervous today 
 
8. I feel happy today 
 
9. It was hard to stay 
in my seat today 
 
10. I feel dizzy today 
 
11. Playing with friends 
was fun today 
 
12. It was easy to do my 
work today 
 
13. It was easy to be 
good today 
 
14. I felt slow today 
 
15. It was hard to have 
fun today 
 
 
 
Not at  Little Some  A lot  All the   
 all     bit                 time            
      
 
 
   0      1      2      3      4 
 
     
   0      1      2      3      4 
 
   0      1      2      3      4 
 
   0      1      2      3      4 
   0      1      2      3      4 
 
   0      1      2      3      4 
 
   0      1      2      3      4 
 
   0      1      2      3      4 
 
 
   0      1      2      3      4 
 
   0      1      2      3      4 
 
 
   0      1      2      3      4 
 
 
   0      1      2      3      4 
 
 
   0      1      2      3      4 
 
   0      1      2      3      4 
 
   0      1      2      3      4 
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APPENDIX B - TEACHER RATING SCALE
Side Effects Rating Scale 
Recess Monitor/Teacher 
Version 
 
Behavior 
Stares a lot or daydreams 
Talks less with others 
Uninterested in others  
Decreased appetite 
Irritable 
Stomachaches 
Headaches 
Drowsiness 
Sad/unhappy 
Prone to crying/whining 
Anxious 
Bites fingernails 
Euphoric/unusually happy 
Dizziness 
Tics or nervous movements 
Playful with others 
Played alone 
Socially withdrawn 
Nail biting 
Skin picking 
 
 
 
 
 
 
 
 
 
 
 
Absent               Serious              
0  1  2  3  4  5  6  7  8  9  
0  1  2  3  4  5  6  7  8  9 
0  1  2  3  4  5  6  7  8  9 
0  1  2  3  4  5  6  7  8  9  
0  1  2  3  4  5  6  7  8  9 
0  1  2  3  4  5  6  7  8  9 
0  1  2  3  4  5  6  7  8  9  
0  1  2  3  4  5  6  7  8  9 
0  1  2  3  4  5  6  7  8  9 
0  1  2  3  4  5  6  7  8  9  
0  1  2  3  4  5  6  7  8  9 
0  1  2  3  4  5  6  7  8  9 
0  1  2  3  4  5  6  7  8  9  
0  1  2  3  4  5  6  7  8  9 
0  1  2  3  4  5  6  7  8  9 
0  1  2  3  4  5  6  7  8  9  
0  1  2  3  4  5  6  7  8  9 
0  1  2  3  4  5  6  7  8  9 
0  1  2  3  4  5  6  7  8  9 
0  1  2  3  4  5  6  7  8  9 
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APPENDIX C - STRUCTURED CHILD INTERVIEW 
 
Date:  
 
Participant: 
 
Medication Dose: 
 
1. Do you normally take medication? 
 
 
 
2. What is it called? 
 
 
 
3. Why are you taking __________? 
 
 
 
4. Do you like taking __________? 
 
 
 
5. What is __________ supposed do for you? 
 
 
 
6. Does __________ help you 
a. pay attention to  
     the teacher?      
b.   stay clam?                                       
c.   remain in your   
     seat?                       
d.   keep from fighting?       
e.   to be nice?                                     
f. to walk rather than 
     run?                  
g. to be patient?   
h. Get along with your 
friends?                                
 
 
YES           NO 
YES           NO 
 
YES           NO 
YES           NO 
YES           NO 
 
YES           NO 
YES           NO 
 
YES           NO 
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7. When you take __________, is there anything you dislike 
about the way it makes you feel? 
 
 
 
 
 
8.  Does __________ make you smarter? 
 
 
 
9.  Does __________ make it harder for you the have fun with  
   friends or toys? 
 
 
 
10. Does __________ ever make you feel sick? 
 
 
 
11. If you could stop taking __________, would you? 
 
 
 
12. What would happen if you stopped taking __________? 
 
 
 
13. Do your friends know that you take __________? 
 
 
 
14.  Do you care if they know that you take ___________? 
 
 
 
15. Do you know what Attention Deficit Hyperactivity   
Disorder is? What is it? Do you have it? 
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APPENDIX D  UNSTRUCTURED RECESS GRAPHS 
Figure 1. Percent of intervals with toy play 
Figure 2. Percent of intervals with social play 
Figure 3. Percent of intervals with solitary play 
Figure 4. Percent of intervals with social vocalizations 
Figure 5. Percent of intervals with nonsocial 
vocalizations 
Figure 6. Percent of intervals activity level 
Figure 7. Percent of intervals with anxiety/stereotyped 
behavior 
Figure 8. Percent of intervals with escape attempts 
Figure 9. Percent of intervals with social withdrawal 
Figure 10. Number of steps taken 
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Figure 1. Percent of intervals with toy play. A 
significant decrease was observed for Rick at the 54 mg 
Concerta dose (p<0.001). A significant increase in toy 
play was observed for Randy (p<0.05). 
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Figure 2. Percent of intervals with social play. No 
significant medication effects were observed for social 
play. 
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Figure 3. Percent of intervals with solitary play. A 
significant decrease in solitary play was observed for 
Rick while on the 54 mg dose of Concerta. 
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Figure 4. Percent of intervals with social vocalizations. 
A significant increase in the number of intervals with 
social vocalizations was observed for Eric at the 20 mg 
Adderall dose (p<0.01). A significant decrease in social 
interactions was observed for Ruby while on 20 mg of 
Adderall (p<0.001) 
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Figure 5. Percent of intervals with nonsocial 
vocalizations. No significant medication effects were 
observed for nonsocial vocalizations. 
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Figure 6. Percent of intervals with high activity. A 
significant decrease in activity level was observed for 
Rick at the 54 mg Concerta dose (p<0.001).  
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Figure 7. Percent of intervals with anxiety/stereotyped 
behaviors. A significant increase in anxiety/stereotyped 
behaviors was observed for Rick at the 54 mg Concerta 
dose (p<0.001).  
 
                          
 99
ERIC
0
10
20
30
40
50
60
70
80
90
100
0 5 10 15 20 25 30
SESSIONS
%
 O
F 
IN
TE
R
VA
LS
BRAD
0
10
20
30
40
50
60
70
80
90
100
0 5 10 15 20 25 30
SESSIONS
%
 O
F 
IN
TE
R
VA
LS
RANDY
0
10
20
30
40
50
60
70
80
90
100
0 5 10 15 20 25 30
SESSIONS
%
 O
F 
IN
TE
R
VA
LS
RUBY
0
10
20
30
40
50
60
70
80
90
100
0 3 6 9 12 15
SESSIONS
%
 O
F 
IN
TE
R
VA
LS
JACK
0
10
20
30
40
50
60
70
80
90
100
0 5 10 15 20 25 30
RICK
0
10
20
30
40
50
60
70
80
90
100
0 5 10 15 20 25 30
PLACEBO
PLACEBO
PLACEBO
PLACEBO
PLACEBO
PLACEBO
20 MG ADDERALL
10 MG 
ADDERALL
20 MG DEXEDRINE
54 MG 
CONCERTA
54 MG 
CONCERTA
36 MG 
CONCERTA
36 MG 
CONCERTA
Figure 8. Percent of intervals with escape attempts. A 
significant decrease in escape attempts was observed for 
Rick at both the 36 mg and 54 mg Concerta dose (p<0.05).  
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Figure 9. Percent of intervals with social withdrawal. No 
significant effects were observed for social withdrawal. 
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Figure 10. Number of steps taken. No significant 
medication effects were observed for the number of steps 
taken. 
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APPENDIX E  STRUCTURED SPORTS TRAINING GRAPHS 
 
Figure 1. Percent of intervals with game participation 
Figure 2. Percent of intervals with social vocalizations 
Figure 3. Percent of intervals with nonsocial 
vocalizations 
Figure 4. Percent of intervals with high activity level 
Figure 5. Percent of intervals with anxiety/ stereotyped 
behavior 
Figure 6. Percent of intervals with escape attempts 
Figure 7. Number of steps taken 
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Figure 1. Percent of intervals with game participation.  
Significant increases in game participation were observed 
for Eric (p<0.05), Brad (p<0.001), Randy (p<0.05) and 
Rick (both doses: 36 mg Concerta p<0.005; 56 mg Concerta 
p<0.001).  
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Figure 2. Percent of intervals with social vocalizations. 
A significant decrease in social vocalizations was 
observed for Rick at both the 36 mg the 54 mg Concerta 
dose (p,0.05 and p<0.01, respectively).  
 
 
 
                          
 105
ERIC
0
10
20
30
40
50
60
70
80
90
100
0 5 10 15 20 25 30
SESSIONS
%
 O
F 
IN
TE
R
VA
LS
BRAD
0
10
20
30
40
50
60
70
80
90
100
0 5 10 15 20 25 30
SESSIONS
%
 O
F 
IN
TE
R
VA
LS
RANDY
0
10
20
30
40
50
60
70
80
90
100
0 5 10 15 20 25 30
SESSIONS
%
 O
F 
IN
TE
R
VA
LS
RUBY
0
10
20
30
40
50
60
70
80
90
100
0 2 4 6 8 10 12
SESSIONS
%
 O
F 
IN
TE
R
VA
LS
JACK
0
10
20
30
40
50
60
70
80
90
100
0 5 10 15 20 25 30
SESSIONS
%
 O
F 
IN
TE
R
VA
LS
RICK
0
10
20
30
40
50
60
70
80
90
100
0 5 10 15 20 25 30
SESSIONS
%
 O
F 
IN
TE
R
VA
LS
PLACEBO
PLACEBO
PLACEBO
PLACEBO
PLACEBO
PLACEBO
20 MG 
ADDERALL
10 MG ADDERALL
20 MG 
DEXEDRINE
54 MG 
CONCERTA
54 MG 
CONCERTA
36 MG 
CONCERTA36 MG 
CONCERTA
Figure 3. Percent of intervals with nonsocial 
vocalizations. No significant medication effects for 
nonsocial vocalizations were observed. 
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Figure 4. Percent of intervals with high activity. A 
significant decrease in activity level was observed for 
Brad at the 20 mg Dexedrine dose (p<0.01).  
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Figure 5. Percent of intervals with anxiety/stereotyped 
behaviors. A significant increase in anxiety/stereotyped 
behavior was observed for Brad (p<0.005), Randy (p<0.05) 
and Rick at both the 36 mg and 54 mg dose of Concerta  
(p<0.05 and p<0.001, respectively). The apparent increase 
in anxiety/stereotyped behaviors for Eric did not achieve 
statistical significance (p=0.06).  
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Figure 6. Percent of intervals with escape attempts. A 
significant decrease in escape attempts was observed for 
was observed for Randy at the 54 mg Concerta dose (p<0.05).  
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Figure 7. Number of steps taken. A significant decrease 
in the number of steps taken was observed for Brad at the 
20 mg Dexedrine dose (p<0.005).  
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APPENDIX F  ALONE PLAY GRAPHS 
 
Figure 1. Percent of intervals with toy play 
Figure 2. Percent of intervals with vocalizations 
Figure 3. Percent of intervals with activity level 
Figure 4. Percent of intervals with anxiety/stereotyped 
behavior 
Figure 5. Percent of intervals with escape attempts 
Figure 6. Percent of intervals with steps taken 
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Figure 1. Percent of intervals with toy play. No 
significant medication effects on toy play were observed. 
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Figure 2. Percent of intervals with vocalizations. A 
significant decrease in vocalizations was observed for 
Brad at the 20 mg Dexedrine dose (p<0.01).  
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Figure 3. Percent of intervals with high activity. A 
significant decrease in activity level was observed for 
Eric at the 20 mg Adderall dose (p<0.05).  
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Figure 4. Percent of intervals with anxiety/stereotyped 
behaviors. No significant medication effects were observed 
for anxiety/stereotyped behavior. 
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Figure 5. Percent of intervals with escape attempts. No 
significant medication effects were observed.  
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Figure 6. Number of steps taken. A significant decrease 
in the number of steps taken was observed for Eric on the 
20 mg Adderall dose (p<0.05) and at the 20 mg Dexedrine 
dose (p<0.05).  
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APPENDIX G  TIGER CAMP OBSERVATION GRAPHS 
 
Figure 1. Percent of intervals with game participation 
Figure 2. Percent of intervals with social vocalizations 
Figure 3. Percent of intervals with nonsocial vocalizations 
Figure 4. Percent of intervals with activity level 
Figure 5. Percent of intervals with anxiety/ stereotyped 
behavior 
Figure 6. Percent of intervals with escape attempts 
Figure 7. Percent of intervals with social withdrawal 
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Figure 1. Percent of intervals with game participation. 
An increase in game participation was observed for Randy 
while taking the 54 mg Concerta dose. 
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Figure 2. Percent of intervals with social vocalizations. 
No significant medication effects were observed for social 
vocalizations. 
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Figure 3. Percent of intervals with nonsocial 
vocalizations. No significant medication effects were 
observed for nonsocial vocalizations. 
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Figure 4. Percent of intervals with high activity. No 
significant medication effects for activity level were 
observed. 
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Figure 5. Percent of intervals with anxiety/stereotyped 
behavior. An increase in anxiety/stereotyped behavior was 
observed for Randy at the 54 mg Concerta dose. 
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Figure 6. Percent of intervals with escape attempts. No 
significant effects were observed for escape attempts. 
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Figure 7. Percent of intervals with social withdrawal. No 
significant medication effects for social withdrawal were 
observed. 
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APPENDIX H  SOCIAL REINFORCER ASSESSMENT GRAPHS 
 
Figure 1. Coupons selected while on placebo dose  
Figure 2. Coupons selected while on low dose of stimulant 
medication 
Figure 3. Coupons selected on the high dose of stimulant 
medication 
Figure 4. Total coupons selected 
Figure 5. Percent of coupons selected 
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Figure 1. Coupons selected while on placebo dose. These 
are cumulative graphs depicting the number of each kind 
of coupon selected while on the placebo dose. The data 
show that the children mainly selected peer play coupons 
while on placebo. 
 
 
                          
 127
RICK
0
5
10
15
20
25
30
35
40
45
50
0 2 4 6 8 10
ALONE
PEER
QUIET
N
U
M
BE
R
 O
F 
C
O
U
PO
N
S 
SE
LE
C
TE
D
 
 
 
 
 
Figure 2. Number of coupons selected while on the low 
dose of stimulant medication. This is a cumulative graph 
depicting the number of each kind of coupon selected by 
Rick while on the low dose of stimulant medication (36 mg 
of Concerta). The data show that the Rick mainly selected 
peer play coupons while on the low dose of Concerta. 
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Figure 3. Number of coupons selected while on the high 
dose of stimulant medication. This is a cumulative graph 
depicting the number of each kind of coupon selected by 
the participants while on the high dose of stimulant 
medication. The data show that two of the participants 
selected alone play coupons more frequently while on the 
high dose of stimulant medication. 
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Figure 4. Total number of blocks placed in the bucket. No 
significant medication effects were observed for the total 
number of blocks placed in the bucket. 
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Figure 5. Percent of coupons selected. These graphs show 
that both Brad and Rick selected a higher percentage of 
nonsocial coupons (i.e., alone play and quiet time coupons) 
while on the high dose of stimulant medication. The 
opposite effect was observed for Eric. Eric selected a 
higher percentage of peer play coupons while on the high 
dose of stimulant medication. 
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